HealthTree

Showing 373 trials matching your filters.

Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients o...

To learn if adding epcoritamab to the treatment combination R-miniCVP (rituximab, cyclophosphamide, vincristine, prednisone) can help to control newly diagnosed DLBCL. The safety of this combination will also be studied.

DRUG: Prednisone

DRUG: Rituximab

DRUG: Cyclophosphamide

DRUG: Vincristine

DRUG: Epcoritamab

Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

Background: Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma. Most people with this cancer can be cured. But those who are not cured have a poor prognosis. Researchers want to add another drug to standard treatment see i...

DRUG: DA-EPOCH

BIOLOGICAL: Rituximab

DRUG: CHOP

DRUG: Acalabrutinib

CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies

This phase I trial studies the effects of CD-19 directed chimeric antigen receptor (CAR)-T cell therapy for the treatment of patients with B cell malignancies that have come back (recurrent) or have not responded to treatment (refractory). CD-19 CAR-...

BIOLOGICAL: Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563

DRUG: Bendamustine

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

DRUG: Cyclophosphamide

DRUG: Fludarabine

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Positron Emission Tomography

Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Unt...

This phase I trial studies the side effects of polatuzumab vedotin when given with combination chemotherapy with or without glofitamab for the treatment of patients with untreated large B-cell lymphoma that grows and spreads quickly and has severe sy...

DRUG: Polatuzumab Vedotin

BIOLOGICAL: Rituximab

DRUG: Prednisone

DRUG: Etoposide

DRUG: Doxorubicin

DRUG: Cyclophosphamide

BIOLOGICAL: Glofitamab

PROCEDURE: Multigated Acquisition Scan

PROCEDURE: Echocardiography

PROCEDURE: FDG-Positron Emission Tomography

PROCEDURE: Computed Tomography

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

Study of E7777 Prior to Kymriah for R/R DLBCL

This is a single institution Phase I study to determine the maximum tolerated dose (MTD) of E7777 when given prior to cyclophosphamide/fludarabine (CY/Flu) lymphodepletion (LD) chemotherapy and Kymriah, a commercial tisagenlecleucel product, for the ...

DRUG: E7777

Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Und...

This phase II clinical trial evaluates whether a modified modality of conditioning reduces treatment-related mortality (TRM) in patients who undergo a hematopoietic stem cell transplant (HSCT) for a hematological malignancy. HSCT is a curative therap...

DRUG: Fludarabine

RADIATION: Total-Body Irradiation

PROCEDURE: Donor Lymphocyte Infusion

DRUG: Cyclophosphamide

DRUG: Tacrolimus

DRUG: Mycophenolate Mofetil

PROCEDURE: Hematopoietic Cell Transplantation

DRUG: Melphalan

PROCEDURE: Bone Marrow Aspiration and Biopsy

PROCEDURE: Diagnostic Imaging

PROCEDURE: Biospecimen Collection

Venetoclax Plus Inotuzumab for B-ALL

This research study is evaluating the safety and efficacy of administering venetoclax and inotuzumab ozogamicin in combination in patients with acute lymphoblastic leukemia (ALL) The names of the study drugs involved in this study are: * Venetoclax...

DRUG: Venetoclax

DRUG: Dexamethasone

DRUG: Inotuzumab Ozogamicin

Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma

This phase II trial tests how well lenalidomide and epcoritamab works in treating patients with follicular lymphoma that has not been previously treated. Although follicular lymphoma is incurable, prognosis has improved for both early and advanced st...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

OTHER: Electronic Health Record Review

BIOLOGICAL: Epcoritamab

DRUG: Lenalidomide

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Positron Emission Tomography

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas T...

This phase I trial tests the safety, side effects, and best dose of combination therapy with tazemetostat and belinostat in treating patients with lymphomas that have returned (relapsed) or resisted treatment (refractory). Tazemetostat is in a class ...

DRUG: Belinostat

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

OTHER: Pharmacokinetic Study

PROCEDURE: Positron Emission Tomography and Computed Tomography Scan

DRUG: Tazemetostat

Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymp...

This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL. The study will include a Phase 1 part to determine the recommended dose of JCAR017 monotherap...

BIOLOGICAL: JCAR017 (lisocabtagene maraleucel)

BIOLOGICAL: JCAR017 (lisocabtagene maraleucel) + ibrutinib

BIOLOGICAL: JCAR017 (lisocabtagene maraleucel) + venetoclax

Allo HSCT Using RIC and PTCy for Hematological Diseases

This is a Phase II study following subjects proceeding with our Institutional non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related, unrelated, or partially matched family donor stem ce...

BIOLOGICAL: Peripheral Blood Stem Cell Transplant

DRUG: Allopurinol 300 MG

DRUG: Fludarabine

DRUG: Cyclophosphamide

BIOLOGICAL: Bone Marrow Cell Transplant

RADIATION: Total Body Irradiation

DRUG: Sirolimus Pill

DRUG: Mycophenolate Mofetil

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

This is a phase I, multi-center, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and clinical activity of LP-168 in subjects with relapsed or refractory B-cell malignancies. LP-168 is a small molecule inhibito...

DRUG: LP-168

Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B...

This phase II trial studies the safety and how well of loncastuximab tesirine when given together with mosunetuzumab works in treating patients with diffuse large B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refract...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

BIOLOGICAL: Loncastuximab Tesirine

BIOLOGICAL: Mosunetuzumab

PROCEDURE: Positron Emission Tomography

Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia

This phase II trial investigates the how well acalabrutinib and obinutuzumab work in treating patients with chronic lymphocytic leukemia (CLL). Acalabrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. I...

DRUG: Acalabrutinib

BIOLOGICAL: Obinutuzumab

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituxi...

This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma (a type of non-Hodgkin lymphoma or NHL). This study will be made up of ...

DRUG: Odronextamab

DRUG: Rituximab

DRUG: Cyclophosphamide

DRUG: Doxorubicin

DRUG: Vincristine

DRUG: Prednisone/prednisolone

DRUG: Bendamustine

Metabolically Fit CD19 CAR T-cell Therapy with CD34 Selection in Patients with CD19+ Relapsed/Refrac...

This is a single-center, nonrandomized, open-label dose-escalation study followed by dose-expansion of CD19- CD34t metabolically programmed CAR T-cell therapy in adult patients with relapsed or refractory CD19 B-cell non-Hodgkin lymphoma (NHL) or chr...

DRUG: Cyclophosphamide injection

DRUG: Fludarabine Injection

BIOLOGICAL: CD19-CD34t metabolically programmed CAR transduced T-cells

CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)

This study is for patients who have lymphoma or leukemia that has come back or has not gone away after treatment. Because there is no standard treatment for this cancer, patients are being asked to volunteer for a gene transfer research study using s...

GENETIC: CD19.CAR-aNKT cells

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults...

This phase II trial studies how well naive T-cell depletion works in preventing chronic graft-versus-host disease in children and young adults with blood cancers undergoing donor stem cell transplant. Sometimes the transplanted white blood cells from...

RADIATION: Total-Body Irradiation

DRUG: Thiotepa

DRUG: Fludarabine

DRUG: Cyclophosphamide

DRUG: Busulfan

PROCEDURE: Allogeneic Bone Marrow Transplantation

DRUG: Tacrolimus

DRUG: Methotrexate

PROCEDURE: Naive T Cell-Depleted Hematopoietic Stem Cell Transplantation

PROCEDURE: Echocardiography

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

Mevrometostat Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Folli...

A Phase 1 Dose Escalation and Expanded Cohort Study Of PF-06821497 (Mevrometostat) in Adult Patients With Relapsed/Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) And Follicular Lymphoma (FL).

DRUG: Mervometostat (PF-06821497)

DRUG: Enzalutamide

Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma

This is an international, first-in-human, multicenter, open-label Phase 1/2 study to evaluate the safety profile, tolerability of IPH6501, and determine the recommended phase 2 dose (RP2D) for patients with B-Cell non-Hodgkin lymphoma.

DRUG: IPH6501

Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies

This study is a multi-center study to evaluate the safety of KUR-502 in subjects with refractory/relapsed B-cell NHL or leukemia (ALL or CLL).

GENETIC: KUR-502

Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukem...

This phase II trial tests whether the pneumococcal pneumonia vaccine series (PCV20 and PPSV23) works to mount an effective immune response in patients with chronic lymphocytic leukemia. PCV20 and PPSV23 are both vaccines that protect against bacteria...

BIOLOGICAL: Pneumococcal 20-valent Conjugate Vaccine

BIOLOGICAL: Pneumococcal Polyvalent Vaccine

OTHER: Questionnaire Administration

A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell N...

This study is researching an investigational drug, odronextamab, in adult patients B-cell non-Hodgkin's lymphoma (B-NHL). The main purpose of this study is to assess the effectiveness of odronextamab in destroying cancer cells and to learn more abou...

DRUG: Odronextamab

Radiation Therapy and Rituximab in Treating Patients With Stage I-II Grade 1 or Grade 2 Follicular L...

This randomized phase I/II trial studies radiation therapy and rituximab in treating patients with stage I-II grade 1 or grade 2 follicular lymphoma. Radiation therapy uses high energy x-rays to kill cancer cells. Immunotherapy with monoclonal antibo...

OTHER: Clinical Observation

RADIATION: Radiation Therapy

BIOLOGICAL: Rituximab

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide,...

The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.

BIOLOGICAL: Zilovertamab vedotin

BIOLOGICAL: Rituximab

DRUG: Cyclophosphamide

DRUG: Doxorubicin

BIOLOGICAL: Rituximab Biosimilar

DRUG: Prednisone

DRUG: Prednisolone

DRUG: Vincristine

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Agg...

The purpose of this study is to assess the safety and tolerability of zilovertamab vedotin as monotherapy and in combination in participants with select B-cell lymphomas including mantle cell lymphoma (MCL), Richter's transformation lymphoma (RTL), f...

BIOLOGICAL: Zilovertamab vedotin

DRUG: Nemtabrutinib

Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or...

This early phase I clinical trial evaluates bridging radiation therapy given before chimeric antigen receptor (CAR) T-cell infusion to treat large B-cell lymphoma (LBCL) that has come back (relapsed) or has not responded to previous treatment (refrac...

PROCEDURE: Biospecimen Collection

BIOLOGICAL: Chimeric Antigen Receptor T-Cell Therapy

PROCEDURE: Computed Tomography

RADIATION: External Beam Radiation Therapy

PROCEDURE: Leukapheresis

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Positron Emission Tomography

Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas

This is a multicenter, open-label, Phase 1 study that will be conducted in two parts. Part 1 is the dose escalation of APG-5918. Part 2 is the dose expansion of APG-5918. APG-5918 will be administered orally. Patients will be treated in 28-day cycle...

DRUG: APG-5918

A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients with DLBCL

The purpose of this study is to test the effectiveness and safety of polatuzumab vedotin in combination with R-miniCHP in patients 75 years and older with DLBCL.

DRUG: Polatuzumab vedotin

DRUG: Rituximab

DRUG: Cyclophosphamide

DRUG: Doxorubicin

DRUG: Prednisone

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic ...

This is a first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia (B-ALL). The purpose of this study is to evaluate the safety a...

BIOLOGICAL: UCART22

BIOLOGICAL: CLLS52

Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorder...

This phase Ib trial tests the safety and effectiveness of epcoritamab in treating patients with post-transplant lymphoproliferative disorder (PTLD) that has come back after a period of improvement (relapsed) or has not responded to previous treatment...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

BIOLOGICAL: Epcoritamab

PROCEDURE: Positron Emission Tomography

Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of D...

This phase I/II trial tests the safety of tafasitamab, retifanlimab, and rituximab (TRR) as a prephase treatment and in combination with standard therapy consisting off cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or polatuzumab ...

PROCEDURE: Bone Marrow Biopsy

DRUG: Cyclophosphamide

DRUG: Doxorubicin

DRUG: Prednisone

BIOLOGICAL: Retifanlimab

BIOLOGICAL: Rituximab and Hyaluronidase Human

BIOLOGICAL: Tafasitamab

DRUG: Vincristine

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Multigated Acquisition Scan

OTHER: Fludeoxyglucose F-18

PROCEDURE: Positron Emission Tomography

PROCEDURE: Computed Tomography

PROCEDURE: Biospecimen Collection

DRUG: Polatuzumab Vedotin

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction Wi...

The goal of this clinical research study is to learn about the safety of giving immune cells called natural killer (NK) cells with chemotherapy to patients with leukemia, lymphoma, or multiple myeloma. Immune system cells (such as NK cells) are made...

DRUG: Cyclophosphamide

DRUG: CAR.70/IL15-transduced CB-NK cells

DRUG: Fludarabine phosphate

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relaps...

The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study hypotheses are that the combination of nemtabrutinib plus v...

DRUG: Nemtabrutinib

DRUG: Venetoclax

BIOLOGICAL: Rituximab

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) infusion to patients with lymphoid malignancies.

DRUG: AVM0703

Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Ma...

B-cell malignancies are a group of cancers of B lymphocytes, a type of white blood cell responsible for fighting infections. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-525 as a monot...

DRUG: ABBV-525

A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)

Participants will have a sample of their white blood cells, called T cells, collected using a procedure called leukapheresis. The collected T cells will be sent to a laboratory to be changed (modified) to become 19-28z/IL-18, the CAR T-cell therapy t...

BIOLOGICAL: 19-28z/IL-18 CAR T cells

NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-...

This phase Ib trial studies the effects of NKTR-255 in combination with chimeric antigen (CAR)-T cell therapy and to see how well they work in treating patients with large B-cell lymphoma that has come back (relapsed) or does not respond to treatment...

DRUG: Cyclophosphamide

DRUG: Fludarabine

BIOLOGICAL: Lisocabtagene Maraleucel

DRUG: Polymer-conjugated IL-15 Receptor Agonist NKTR-255

PROCEDURE: X-Ray Imaging

PROCEDURE: Echocardiography

PROCEDURE: Multigated Acquisition Scan

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Lumbar Puncture

PROCEDURE: Computed Tomography

PROCEDURE: Positron Emission Tomography

PROCEDURE: Biospecimen Collection

PROCEDURE: Biopsy

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refr...

This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back (relapsed) or does not respond to treatment (refractory). I...

DRUG: Asparaginase Erwinia chrysanthemi

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration and Biopsy

DRUG: Calaspargase Pegol

DRUG: Cyclophosphamide

DRUG: Cytarabine

PROCEDURE: Diagnostic Imaging

BIOLOGICAL: Inotuzumab Ozogamicin

DRUG: Leucovorin Calcium

PROCEDURE: Lumbar Puncture

DRUG: Methotrexate

DRUG: Pegaspargase

DRUG: Vincristine

Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T C...

This phase I trial evaluates the best dose, possible benefits and/or side effects of fludarabine and cyclophosphamide with or without rituximab before CD19 chimeric antigen receptor T cells in treating patients with diffuse large B-cell lymphoma that...

BIOLOGICAL: Chimeric Antigen Receptor T-Cell Therapy

DRUG: Cyclophosphamide

DRUG: Fludarabine Phosphate

BIOLOGICAL: Rituximab

T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

This is an open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety of an autologous T-cell therapy (EB103) and to determine the Recommended Phase II Dose (RP2D) in adult subjects (≥ 18 years of age) who have relapsed...

BIOLOGICAL: EB103

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-102...

The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Richter's transformation, marg...

DRUG: Nemtabrutinib

A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Co...

The participants of this study would have relapsed/refractory follicular lymphoma. Follicular lymphoma is a type of blood cancer. It is referred to as 'relapsed' when the disease has come back after a period of improvement after that follows a treat...

DRUG: Tazemetostat

DRUG: Placebo oral tablet

COMBINATION_PRODUCT: Lenalidomide

COMBINATION_PRODUCT: Rituximab

Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insuffi...

This partially randomized clinical trial studies cholecalciferol in improving survival in patients with newly diagnosed cancer with vitamin D insufficiency. Vitamin D replacement may improve tumor response and survival and delay time to treatment in ...

DIETARY_SUPPLEMENT: Cholecalciferol

OTHER: Laboratory Biomarker Analysis

Epcoritamab and Rituximab for First-line Follicular Lymphoma

The purpose of this study is to determine how effective and safe the combination of rituximab and epcoritamab is in treating patients with Follicular Lymphoma (FL) and who have not received other treatments for their lymphoma. The names of the study...

DRUG: Epcoritamab

DRUG: Rituximab

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared t...

The primary purpose of the study is to evaluate whether biweekly administered XEMBIFY® plus Standard Medical Treatment (SMT) over a one-year period will reduce the rate of major bacterial infections per participant per year in B-cell CLL, MM, and NHL...

DRUG: Xembify

DRUG: Placebo

Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT

This trial will assess the feasibility of alpha/beta T-cell and B-cell depleted allogeneic hematopoietic cell transplantation (HCT) followed by blinatumomab therapy for high-risk B cell acute lymphoblastic leukemia (ALL) as a means of reducing rates ...

DEVICE: Alpha/Beta T-cell and B-cell depleted HCT

DRUG: Blinatumomab

Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refra...

The goal of this clinical study is test how well the study drug, axicabtagene ciloleucel, works in participants with relapsed/refractory follicular lymphoma

BIOLOGICAL: Axicabtagene Ciloleucel

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: Lenalidomide

DRUG: Rituximab

DRUG: Doxorubicin

DRUG: Vincristine

DRUG: Prednisone

DRUG: Bendamustine

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory So...

This phase I/II trial tests the safety, side effects, and best dose of entinostat and ZEN003694 in treating patients with solid tumors or lymphoma that has spread to other places in the body (advanced) or does not respond to treatment (refractory). E...

DRUG: BET Bromodomain Inhibitor ZEN-3694

PROCEDURE: Core Biopsy

DRUG: Entinostat

A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Rela...

To find a recommended dose of valemetostat that can be given in combination with rituximab and lenalidomide to patients with follicular lymphoma. The safety and effects of this drug combination will also be studied

DRUG: Rituximab

DRUG: Lenalidomide

DRUG: Valemetostat

Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lympho...

This phase I trial tests the safety, side effects, and best dose of venetoclax in combination with a pediatric-inspired chemotherapy regimen known as C10403 in treating patients with newly diagnosed B cell acute lymphoblastic leukemia. Venetoclax may...

DRUG: Cyclophosphamide

DRUG: Cytarabine

DRUG: Daunorubicin Hydrochloride

DRUG: Mercaptopurine

DRUG: Methotrexate

DRUG: Pegaspargase

DRUG: Prednisone

DRUG: Venetoclax

DRUG: Vincristine Sulfate

A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refrac...

This phase II trial tests the safety and best dose of revumenib in combination with chemotherapy, and evaluates whether this treatment improves the outcome in infants and young children who have leukemia that has come back (relapsed) or does not resp...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

DRUG: Calaspargase Pegol

DRUG: Cytarabine

PROCEDURE: Echocardiography

DRUG: Fludarabine Phosphate

DRUG: Hydrocortisone Sodium Succinate

PROCEDURE: Lumbar Puncture

DRUG: Methotrexate

PROCEDURE: Multigated Acquisition Scan

DRUG: Prednisolone

DRUG: Prednisone

DRUG: Revumenib

DRUG: Vincristine Sulfate

A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent ...

The purpose of this study is to define the recommended Phase 2 Dose, safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 during monotherapy and in combination with lenalidomide and/or rituximab in patients with indolent NHL

BIOLOGICAL: EO2463

DRUG: lenalidomide

BIOLOGICAL: rituximab

Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblas...

This trial aims to demonstrate the feasibility of this approach to reliably generate product and to safely administer the product to patients who have B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia.

DRUG: Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous)

Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma

The main purpose of this study to find the ideal dose for the combination treatment of Zanubrutinib and Tafasitamab in patients with mantle cell lymphoma. Another purpose is to assess how well the combination treatment works in patients with the stud...

DRUG: Zanubrutinib

DRUG: Tafasitamab

Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission ...

This phase II trial compares epcoritamab to standard practice (observation) for the treatment of patients with B-cell lymphomas who are not in complete remission after treatment with CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy. Epc...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

BIOLOGICAL: Epcoritamab

PROCEDURE: Magnetic Resonance Imaging

OTHER: Patient Observation

PROCEDURE: Positron Emission Tomography

Loncastuximab Tesirine in Combination with DA-EPOCH-R in Patients with Previously Untreated Aggressi...

The overarching hypothesis for this study is that a safe and tolerable dose (i.e., the maximum tolerated dose) will be identified for loncastuximab tesirine in combination with dose-adjusted etoposide phosphate, prednisone, vincristine sulfate (Oncov...

DRUG: Etoposide

DRUG: Doxorubicin

DRUG: Cyclophosphamide

DRUG: Rituximab

DRUG: Vincristine

DRUG: Prednisone

DRUG: Loncastuximab Tesirine 0.075 mg/kg by IV

DRUG: Loncastuximab tesirine 0.12 mg/kg by IV

DRUG: Loncastuximab tesirine 0.15 mg/kg by IV

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Rela...

The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refractory (R/R) ma...

DRUG: Obinutuzumab

DRUG: Glofitamab

DRUG: Rituximab

DRUG: Bendamustine

DRUG: Lenalidomide

DRUG: Tocilizumab

A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relap...

To learn if giving mosunetuzumab in combination with polatuzumab vedotin, tafasitamab, and lenalidomide can help to control relapsed/refractory FL and DLBCL.

DRUG: Mosunetuzumab

DRUG: Polatuzumab vedotin

DRUG: Tafasitamab

DRUG: Lenalidomide

PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibit...

This phase II trial studies the effect of brentuximab vedotin and nivolumab alone and in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone in treating patients with untreated, stage I-IV primary mediastinal large B-cell lympho...

DRUG: Brentuximab Vedotin

DRUG: Cyclophosphamide

DRUG: Doxorubicin

BIOLOGICAL: Nivolumab

DRUG: Prednisone

OTHER: Quality-of-Life Assessment

BIOLOGICAL: Rituximab

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

Dose Escalation - Determine the maximum tolerated dose (MTD), if possible, or minimum optimal biologic dose (OBD), and evaluate the safety and tolerability of VIP943 in subjects with advanced CD123+ hematologic malignancies

DRUG: VIP943 (QW)

DRUG: VIP943 (BIW)

Tegavivint for Treating Patients with Relapsed or Refractory Large B-Cell Lymphoma

This phase I trial tests the safety, side effects, and best dose of tegavivint in treating patients with large b-cell lymphomas that has come back (relapsed) or does not respond to treatment (refractory). Tegavivint may stop the growth of cancer cell...

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

PROCEDURE: Positron Emission Tomography

DRUG: Tegavivint

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatmen...

This phase II trial studies how well a donor stem cell transplant, treosulfan, fludarabine, and total-body irradiation work in treating patients with blood cancers (hematological malignancies). Giving chemotherapy and total-body irradiation before a ...

PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation

DRUG: Cyclophosphamide

DRUG: Cyclosporine

BIOLOGICAL: Filgrastim

DRUG: Fludarabine

DRUG: Mycophenolate Mofetil

DRUG: Mycophenolate Sodium

RADIATION: Total-Body Irradiation

DRUG: Treosulfan

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Echocardiography

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

PROCEDURE: Positron Emission Tomography

Epcoritamab in Patients with Follicular Lymphoma Not Accomplishing a CR with Upfront Chemoimmunother...

This research is being done to see if epcoritamab is effective in treating follicular lymphoma as a second line of treatment. The name of the study drug in this research study is: -Epcoritamab (a type of antibody)

DRUG: Epcoritamab

Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Mini...

This phase II trial studies how well inotuzumab ozogamicin works in treating patients with B-cell acute lymphocytic leukemia with positive minimal residual disease. Inotuzumab ozogamicin is a monoclonal antibody called inotuzumab linked to a toxic ag...

BIOLOGICAL: Inotuzumab Ozogamicin

The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescent...

This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before receiving a hematopoietic cel...

DIAGNOSTIC_TEST: NGS-MRD

DRUG: Myeloablative allogeneic HCT with a non-TBI conditioning regimen

Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients with Chronic Lymphocytic Leukemia (C...

The purpose of this study is to determine the rate of minimum residual disease (MRD) negative response (i.e. the rate of no evidence of disease) of the study drugs, zanubrutinib, obinutuzumab, and venetoclax, given in combination as a treatment for C...

DRUG: Zanubrutinib

DRUG: Obinutuzumab

DRUG: Venetoclax

SPARK-ALL: Calaspargase Pegol in Adults With ALL

The purpose of this phase 2/3 study is to confirm the recommended doses and to evaluate the safety and pharmacodynamics of Calaspargase pegol for the treatment of adult patients with Philadelphia-negative Acute Lymphoblastic Leukemia.

DRUG: Calaspargase pegol (S95015)

Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Le...

This phase II trial studies how well ibrutinib and blinatumomab work in treating patients with B acute lymphoblastic leukemia that has come back or is not responding to treatment. Ibrutinib may stop the growth of cancer cells by blocking some of the ...

BIOLOGICAL: Blinatumomab

DRUG: Ibrutinib

Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

This phase II trial investigates how well brentuximab vedotin and bendamustine work in treating patients with follicular lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Brentuximab vedotin is a monoclonal antibod...

DRUG: Bendamustine Hydrochloride

DRUG: Brentuximab Vedotin

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine a...

This phase I trial tests safety, side effects and best dose of B-cell activating factor receptor (BAFFR)-based chimeric antigen receptor T-cells, with fludarabine and cyclophosphamide lymphodepletion, for the treatment of patients with B-cell hematol...

BIOLOGICAL: Autologous BAFFR-targeting CAR T Cells

DRUG: Bendamustine

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration and Biopsy

PROCEDURE: Computed Tomography

DRUG: Cyclophosphamide

PROCEDURE: Echocardiography

DRUG: Fludarabine

PROCEDURE: Leukapheresis

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Positron Emission Tomography

Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refracto...

This phase Ib trial tests the safety, side effects, and effectiveness of humanized (hu)CD19-chimeric antigen receptor (CAR) T cell therapy in treating patients with CD19 positive B-cell acute lymphoblastic leukemia (ALL) that has come back after a pe...

PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

BIOLOGICAL: CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes

BIOLOGICAL: Cetuximab

PROCEDURE: Computed Tomography

DRUG: Cyclophosphamide

PROCEDURE: Echocardiography

DRUG: Fludarabine

PROCEDURE: Leukapheresis

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Multigated Acquisition Scan

PROCEDURE: Positron Emission Tomography

Study of CTO1681 for the Prevention and Treatment of CRS in DLBCL Patients Receiving CAR T-Cell Ther...

This is an interventional study to evaluate the use of CTO1681 in preventing or reducing CAR T-cell-induced toxicities like cytokine release syndrome (CRS). This study will enroll adult patients with DLBCL who are scheduled to receive CD19-directed C...

DRUG: CTO1681 10 μg

DRUG: CTO1681 20 μg

DRUG: CTO1681 30 μg

ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

ACE1831 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment of CD20-expressing B-cell malignancies. The ACE1831-001 study is an open-label, Phase I, first-in-hum...

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: ACE1831

DRUG: Obinutuzumab

A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory ...

To learn if the combination of axicabtagene ciloleucel (axi-cel) and glofitamab as first-line therapy in high-risk LBCL participants or as second-line therapy in LBCL participants can help to control the disease.

DRUG: Glofitamab

DRUG: Obinutuzumab

DRUG: Axi-cel

HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Reduced Dose Post Tra...

The goal of this clinical trial is to determine the effectiveness of Reduced Dose Post-Transplant Cyclophosphamide (PTCy) in patients with hematologic malignancies after receiving an HLA-Mismatched Unrelated Donor (MMUD) . The main question\[s\] it a...

DRUG: Busulfan

DRUG: Fludarabine

PROCEDURE: PBSC Hematopoietic Stem Cell Transplantation (HSCT)

DRUG: Post-Transplant Cyclophosphamide

DRUG: Mesna

DRUG: Tacrolimus

DRUG: Mycophenolate Mofetil

OTHER: Patient Reported Outcomes

DRUG: Melphalan

RADIATION: Total-body irradiation

DRUG: Cyclophosphamide

Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell T...

This phase I/II trial studies how well cytokine-treated veto cells work in treating patients with hematologic malignancies following stem cell transplant. Giving chemotherapy and total-body irradiation before a stem cell transplant helps stop the gro...

BIOLOGICAL: Anti-Thymocyte Globulin

DRUG: Cyclophosphamide

BIOLOGICAL: Cytokine-treated Veto Cells

DRUG: Fludarabine

PROCEDURE: Peripheral Blood Stem Cell Transplantation

RADIATION: Total-Body Irradiation

A Study of Glofitamab and Lenalidomide in People with Mantle Cell Lymphoma

The purpose of this study is to find out whether the combination of glofitamab and lenalidomide is an effective treatment for relapsed or refractory Mantle Cell Lymphoma

DRUG: Glofitamab

DRUG: Obinutuzumab

DRUG: Lenalidomide

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refr...

This phase I trial tests the safety, side effects and best infusion dose of genetically engineered cells called anti-CD19/CD20/CD22 chimeric antigen receptor (CAR) T-cells following a short course of chemotherapy with cyclophosphamide and fludarabine...

BIOLOGICAL: Anti-CD19/CD20/CD22 CAR T-Cells

DRUG: Cyclophosphamide

DRUG: Fludarabine Phosphate

HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclopho...

This is a prospective, multi-center, Phase II study of hematopoietic cell transplantation (HCT) using human leukocyte antigen (HLA)-mismatched unrelated donors (MMUD) for peripheral blood stem cell transplant in adults and bone marrow stem cell trans...

DRUG: Busulfan

DRUG: Fludarabine

RADIATION: Total-body irradiation

DRUG: Cyclophosphamide

DRUG: Melphalan

PROCEDURE: PBSC Hematopoietic Stem Cell Transplantation (HSCT)

PROCEDURE: Bone Marrow Hematopoietic Stem Cell Transplantation

DRUG: Post-transplant Cyclophosphamide

DRUG: Mesna

DRUG: Tacrolimus

DRUG: Mycophenolate Mofetil

OTHER: Patient-Reported Outcomes

A Study of Mosunetuzumab in People With Follicular Lymphoma

The purpose of this study is to find out if mosunetuzumab is an effective treatment in people with follicular lymphoma that was recently diagnosed and have not yet received any treatments for their disease.

DRUG: Mosunetuzumab

DRUG: Zanubrutinib

Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas

This treatment uses T cells already present in the participant's body that have been modified outside of the body by a lentivirus and then returned by an infusion to target the cancer. Lentivirus is a family of viruses that can be used by scientists ...

BIOLOGICAL: UF-KURE19 CAR-T cells

DRUG: Fludarabine

DRUG: Cyclophosphamide

Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma

This phase I/II trial studies the safety of acalabrutinib and axicabtagene ciloleucel in treating patients with B-cell lymphoma. Acalabrutinib may stop the growth of tumor cells by blocking key pathways needed for cell growth. Immunotherapy with axic...

DRUG: Acalabrutinib

BIOLOGICAL: Axicabtagene Ciloleucel

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refract...

The main purpose of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of t...

DRUG: Pirtobrutinib

Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE As Salvage Therapy for Transplant Eligi...

This phase II clinical trial evaluates tafasitamab and lenalidomide followed by tafasitamab and the carboplatin, etoposide and ifosfamide (ICE) regimen as salvage therapy for transplant eligible patients with large B-cell lymphoma that has come back ...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

DRUG: Carboplatin

PROCEDURE: Computed Tomography

DRUG: Etoposide

DRUG: Ifosfamide

DRUG: Lenalidomide

PROCEDURE: Positron Emission Tomography

BIOLOGICAL: Tafasitamab

A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies

ELiPSE-1 is a Phase 1, multi-center, dose-finding study to evaluate the safety, pharmacokinetics, and preliminary efficacy of CNTY-101 in participants with relapsed or refractory cluster of differentiation (CD)19-positive B-cell malignancies.

BIOLOGICAL: CNTY-101

BIOLOGICAL: IL-2

DRUG: Lymphodepleting Chemotherapy

Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291...

Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood cells). The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of ABBV-291 in...

DRUG: ABBV-291

A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Ac...

The researchers are doing this study to see if early reinfusion of tisagenlecleucel can keep participants in B-CEll ApLasia at 6 months after their first infusion. The researchers will also look at the safety of early reinfusion and how effective it ...

BIOLOGICAL: Tisagenlecleucel

Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym

The purpose of the study is to evaluate the safety and efficacy of tafasitamab and lenalidomide in participants with Large B Cell Lymphoma (LBCL) after axicabtagene ciloleucel (axi-cel) treatment. Participants will be asked to spend about 12 months i...

DRUG: Tafasitamab

DRUG: Lenalidomide

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

This is a non-randomized clinical trial to evaluate the safety and efficacy of CD22CART administered after lymphodepleting chemotherapy in adults with relapsed / refractory B Cell Lymphomas. All evaluable participants will be followed for overall sur...

DRUG: CD22CART Infusion

First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With R...

This is an open-label, multicenter, Phase 1/Phase 2, dose escalation and dose expansion study to evaluate the safety, pharmacokinetics, pharmacodynamics and anti-leukemic activity of SAR443579 in various hematological malignancies.

DRUG: SAR443579

Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Othe...

This phase II trial studies the effect of acalabrutinib and obinutuzumab in treating patients with follicular lymphoma or other indolent non-Hodgkin lymphoma for which the patient has not received treatment in the past (previously untreated). Acalabr...

DRUG: Acalabrutinib

BIOLOGICAL: Obinutuzumab

OTHER: Quality-of-Life Assessment

OTHER: Questionnaire Administration

Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lympho...

This phase Ib/II trial is aimed at studying the combination of a drug named Selinexor (selective inhibitor of nuclear export) in combination with standard therapy for B cell Non-Hodgkin's lymphoma called R-CHOP. The investigators will establish maxim...

DRUG: Selinexor

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies.

DRUG: NX-2127

A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies o...

This is a Phase 1, open-label, dose escalation study to determine the safety and preliminary efficacy of voruciclib monotherapy in subjects with relapsed/refractory B cell malignancies or AML after failure of standard therapies or voruciclib in combi...

DRUG: voruciclib monotherapy

DRUG: voruciclib and venetoclax

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Comb...

This study will evaluate the safety, efficacy, and pharmacokinetics of mosunetuzumab or glofitamab in combination with CELMoDs (CC-220 and/or CC-99282) in participants with B-cell NHL.

DRUG: SC Mosunetuzumab

DRUG: IV Glofitamab

DRUG: Iberdomide

DRUG: Golcadomide

DRUG: Obinutuzumab

DRUG: Tocilizumab

Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden ...

To learn if obinutuzumab in combination with CC-99282 can help to control previously untreated, high tumor burden FL

DRUG: Obinutuzumab

DRUG: CC-99282

Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior ...

The primary objective of this study is to evaluate the safety of zanubrutinib (also known as BGB-3111) in chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenström macroglobulinemia, mantle cell lymphoma, or marginal zone lymphoma patients...

DRUG: Zanubrutinib

ADCT-602 in Treating Patients with Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia

This phase I/II trial studies the side effects and best dose of ADCT-602 in treating patients with B-cell lymphoblastic leukemia that has come back or does not respond to treatment. Monoclonal antibodies, such as ADCT-602, may interfere with the abil...

BIOLOGICAL: ADCT-602

Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma

This phase II trial tests the safety, side effects and effectiveness of mosunetuzumab in treating patients with slow growing (indolent) B-cell lymphoma. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow...

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

PROCEDURE: Magnetic Resonance Imaging

BIOLOGICAL: Mosunetuzumab

PROCEDURE: Positron Emission Tomography

OTHER: Questionnaire Administration

Co-administration of CART22-65s and huCART19 for B-ALL

This study will evaluate the safety and efficacy of administering two CAR T cell products, huCART19 and CART22-65s, in children with advanced B cell Acute Lymphoblastic Leukemia (B-ALL).

BIOLOGICAL: Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)

BIOLOGICAL: Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)

Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy

The purpose of the study is to evaluate whether receiving the pneumococcal 13-valent conjugate vaccine (PCV13) before and after CD19-targeted CAR T cell therapy will optimize cellular and humoral immunity to pneumococcus.

BIOLOGICAL: Pneumococcal conjugate vaccine (PCV13)

BIOLOGICAL: CD19 targeted CAR T Cell Therapy

Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

The purpose of this study is to determine if giving an experimental drug called venetoclax in combination with lenalidomide and rituximab is safe and effective for treating people with Mantle Cell Lymphoma (MCL).

DRUG: Venetoclax

DRUG: Lenalidomide

DRUG: Rituximab

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabru...

The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior therapy. Th...

DRUG: Nemtabrutinib

DRUG: Ibrutinib

DRUG: Acalabrutinib

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With ...

This phase II/III trial compares the side effects and activity of oral azacitidine in combination with the standard drug therapy (reduced dose rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone \[R-miniCHOP\]) versus R-miniCHOP alon...

PROCEDURE: Biospecimen Collection

DRUG: Cyclophosphamide

DRUG: Doxorubicin Hydrochloride

DRUG: Oral Azacitidine

DRUG: Prednisone

OTHER: Questionnaire Administration

BIOLOGICAL: Rituximab

DRUG: Vincristine Sulfate

Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma

Background: Primary effusion lymphoma (PEL) is an aggressive form of cancer that affects cells in the immune system and lymph nodes. How PEL develops is not well understood, and this disease does not respond well to standard treatments for other typ...

DRUG: Daratumumab SC

Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia

This trial is a limited multi-center, Phase II study to evaluate inotuzumab ozogamicin (Besponsa) in pediatric patients with MRD positive CD22-positive B-lymphoblastic leukemia (B-ALL). Some patients with newly diagnosed ALL maintain low levels of M...

DRUG: Inotuzumab ozogamicin

DRUG: Methotrexate

DRUG: Hydrocortisone

DRUG: Cytarabine

DRUG: Diphenhydramine

DRUG: Acetaminophen

DRUG: Methylprednisolone

A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Youn...

The purpose of this study is to evaluate the safety and efficacy of glofitamab, as monotherapy and in combination with a standard chemoimmunotherapy regimen: rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) in pediatric and young adult parti...

DRUG: Obinutuzumab

DRUG: Glofitamab

DRUG: Rituximab

DRUG: Ifosfamide

DRUG: Carboplatin

DRUG: Etoposide

DRUG: Tocilizumab

IKS03 in Patients with Advanced B Cell Non-Hodgkin Lymphomas

This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, antineoplastic activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS03, a CD19 targeting antibody-drug conjugate, in...

DRUG: IKS03

CAR T-cell Therapy in Patients With Renal Dysfunction

This is a prospective, descriptive study designed to assess the feasibility of administering CAR T therapy among patients with moderate to severe renal impairment using dose adjusted lymphodepleting chemotherapy.

DRUG: Fludarabine

DRUG: Cyclophosphamide

Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma

This phase II trial compares the safety, side effects and effectiveness of reduced dose radiation therapy to standard of care dose radiation in treating patients with indolent non-Hodgkin lymphoma. Radiation therapy uses high energy x-rays, particles...

PROCEDURE: Computed Tomography

PROCEDURE: Endoscopic Procedure

RADIATION: Involved-site Radiation Therapy (3 Fractions)

RADIATION: Involved-site Radiation Therapy (12 Fractions)

PROCEDURE: Positron Emission Tomography

OTHER: Questionnaire Administration

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recu...

Background: Acute lymphoblastic leukemia (ALL) is the most common cancer in children. About 90% of children and young adults who are treated for ALL can now be cured. But if the disease comes back, the survival rate drops to less than 50%. Better tr...

BIOLOGICAL: CD19/CD22-CAR-transduced T cells

DRUG: cyclophosphamide

DRUG: fludarabine

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mix...

This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phe...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Bone Scan

DRUG: Calaspargase Pegol

PROCEDURE: Computed Tomography

DRUG: Cyclophosphamide

DRUG: Cytarabine

DRUG: Daunorubicin Hydrochloride

DRUG: Dexamethasone

DRUG: Doxorubicin Hydrochloride

BIOLOGICAL: Inotuzumab Ozogamicin

DRUG: Leucovorin Calcium

PROCEDURE: Magnetic Resonance Imaging

DRUG: Mercaptopurine

DRUG: Methotrexate

DRUG: Pegaspargase

PROCEDURE: Positron Emission Tomography

DRUG: Prednisolone

OTHER: Questionnaire Administration

RADIATION: Radiation Therapy

DRUG: Thioguanine

DRUG: Vincristine Sulfate

Study to Evaluate the Efficacy and Safety of Sonrotoclax in Participants With Waldenström's Macroglo...

This study will evaluate the safety and efficacy of the BCL2 inhibitor BGB-11417 (sonrotoclax) in participants with relapsed/refractory Waldenström's Macroglobulinemia (R/R WM) and in combination with zanubrutinib in adult participants with previousl...

DRUG: BGB-11417

DRUG: Zanubrutinib

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large ...

This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen receptor (CAR) T-cell therapy (tisagenlecleucel, axicabta...

BIOLOGICAL: Axicabtagene Ciloleucel

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

DRUG: Cyclophosphamide

DRUG: Fludarabine

BIOLOGICAL: Lisocabtagene Maraleucel

BIOLOGICAL: Mosunetuzumab

OTHER: Patient Observation

DRUG: Polatuzumab Vedotin

PROCEDURE: Positron Emission Tomography

BIOLOGICAL: Tisagenlecleucel

Acalabrutinib and Venetoclax with or Without Early Obinutuzumab for the Treatment of High Risk, Recu...

This phase II trial studies how well acalabrutinib and venetoclax with or without early obinutuzumab work for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma that is high risk, has come back (recurrent), or does not respon...

DRUG: Acalabrutinib

BIOLOGICAL: Obinutuzumab

DRUG: Venetoclax

Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma

This study will have two Phases: Phase 1a and Phase 1b. The goal of Phase 1a of this clinical study is to learn more about the safety, tolerability and dosing of study drug KITE-197, in participants with relapsed or refractory large B-cell lymphoma (...

DRUG: KITE-197

DRUG: Cyclophosphamide

DRUG: Fludarabine

A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Thera...

To learn if giving acalabrutinib, rituximab, and brexucabtagene autoleucel to patients with previously untreated high-risk mantle cell lymphoma (MCL) can help to control the disease.

DRUG: Acalabrutinib

DRUG: Rituximab

OTHER: Brexucabtagene Autoleucel

DRUG: Cyclophosphamide

DRUG: Fludarabine Phosphate

Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants Wi...

The purpose of this study is to evaluate the efficacy of loncastuximab tesirine (ADCT-402) combined with rituximab compared to standard immunochemotherapy.

DRUG: Loncastuximab Tesirine

DRUG: Rituximab

DRUG: Gemcitabine

DRUG: Oxaliplatin

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating P...

This phase II trial studies how well blinatumomab, inotuzumab ozogamicin, and combination chemotherapy work as frontline therapy in treating patients with B acute lymphoblastic leukemia. Immunotherapy with monoclonal antibodies, such as blinatumomab,...

BIOLOGICAL: Blinatumomab

DRUG: Cyclophosphamide

DRUG: Cytarabine

DRUG: Dexamethasone

DRUG: Doxorubicin Hydrochloride

BIOLOGICAL: Inotuzumab Ozogamicin

OTHER: Laboratory Biomarker Analysis

DRUG: Mercaptopurine

DRUG: Methotrexate

BIOLOGICAL: Ofatumumab

DRUG: Prednisone

BIOLOGICAL: Rituximab

DRUG: Vincristine Sulfate

Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy

This is a multicenter Phase 1b study evaluating the safety, tolerability, and preliminary anti-tumor activity of NT-I7 administration following standard of care CD19 CAR T-cell therapy for eligible subjects with r/r LBCL.

DRUG: Efineptakin alfa

DRUG: Tisagenlecleucel

DRUG: Axicabtagene ciloleucel

DRUG: Lisocabtagene Maraleucel

Gene Therapy for B-Cell Acute Lymphoblastic Leukemia

This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19+ B-cell acute lymphoblastic leukemia (ALL).

GENETIC: Dose Level 1, VNX-101

GENETIC: Dose Level 2, VNX-101

GENETIC: Dose Level 3, VNX-101

GENETIC: Dose Level 4, VNX-101

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

This phase I trial tests the safety, side effects, and best dose of nivolumab in combination with ASTX727 in treating B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodie...

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

DRUG: Decitabine and Cedazuridine

BIOLOGICAL: Nivolumab

PROCEDURE: Positron Emission Tomography

Blinatumomab Bridging Therapy

The investigator is testing the ability of a biologically active therapy in blinatumomab, an anti-CD19/CD3 bispecific T-cell engager, to further reduce residual leukemia immediately prior to HCT to improve post-HCT outcomes.

DRUG: Blinatumomab

Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic...

This phase Ib trial evaluates the side effects and best dose of choline salicylate given together with a low dose of selinexor in treating patients with non-Hodgkin or Hodgkin lymphoma, or multiple myeloma whose prior treatment did not help their can...

DRUG: Choline Salicylate

DRUG: Selinexor

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib...

This phase II trial studies the effects of venetoclax and rituximab in comparison to ibrutinib and rituximab in treating patients with previously untreated Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Ibrutinib may stop the growth of c...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

DRUG: Ibrutinib

PROCEDURE: Positron Emission Tomography

BIOLOGICAL: Rituximab

DRUG: Venetoclax

Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory...

This is a single-arm, open label, multicenter Phase 1/2 study evaluating ALLO-501A in adult subjects with R/R LBCL and CLL/SLL. The purpose of the ALPHA2 study is to assess the safety, efficacy, and cell kinetics of ALLO-501A in adults with relapsed ...

GENETIC: ALLO-501A

BIOLOGICAL: ALLO-647

DRUG: Fludarabine

DRUG: Cyclophosphamide

Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the ...

This phase II trial studies the effect of rituximab, lenalidomide, acalabrutinib, tafasitamab alone and in combination with chemotherapy in treating patients with newly diagnosed non-germinal center diffuse large B-cell lymphoma. Rituximab and tafasi...

DRUG: Acalabrutinib

DRUG: Cyclophosphamide

DRUG: Doxorubicin Hydrochloride

DRUG: Lenalidomide

DRUG: Prednisone

BIOLOGICAL: Rituximab

BIOLOGICAL: Tafasitamab

DRUG: Vincristine

Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma

This research study combines 2 different ways of fighting disease: antibodies and T cells. Both antibodies and T cells have been used to treat patients with cancers, and both have shown promise, but neither alone has been sufficient to cure most pati...

BIOLOGICAL: iC9-CAR19 T cells

DRUG: Bendamustine

DRUG: Fludarabine

DRUG: AP1903

DRUG: Cyclophosphamide

A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Particip...

The purpose of this study is to assess the efficacy and safety of golcadomide in combination with rituximab in participants with newly diagnosed advanced stage Follicular Lymphoma (FL).

DRUG: Golcadomide

DRUG: Rituximab

DRUG: Cyclophosphamide

DRUG: Doxorubicin

DRUG: Vincristine

DRUG: Prednisone

DRUG: Bendamustine

Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone ...

BrUOG-401 is a prospective, single-arm, phase 2 trial of first-line therapy in adult patients with previously untreated FL or MZL. All patients will be assigned the same initial treatment plan, modified by interim response assessment (IRA) after Cycl...

DRUG: Mosunetuzumab

DRUG: Lenalidomide

CONFIRM: Magnetic Resonance Guided Radiation Therapy

This research is being done to determine the safety and feasibility of using a type of radiation guided by magnetic resonance imaging (MRI) and chemotherapy to treat patients with gastric and breast cancer. The name of the radiation machine involved ...

RADIATION: Viewray MRIdian® Linac

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymp...

This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

BIOLOGICAL: Obinutuzumab

OTHER: Quality-of-Life Assessment

OTHER: Questionnaire Administration

DRUG: Venetoclax

Personalized NK Cell Therapy in CBT

This phase II clinical trial studies how well personalized natural killer (NK) cell therapy works after chemotherapy and umbilical cord blood transplant in treating patients with myelodysplastic syndrome, leukemia, lymphoma or multiple myeloma. This ...

BIOLOGICAL: Allogeneic Natural Killer Cell Line NK-92

BIOLOGICAL: Anti-Thymocyte Globulin

DRUG: Busulfan

DRUG: Clofarabine

DRUG: Cyclophosphamide

DRUG: Fludarabine Phosphate

OTHER: Laboratory Biomarker Analysis

DRUG: Melphalan

BIOLOGICAL: Rituximab

RADIATION: Total-Body Irradiation

PROCEDURE: Umbilical Cord Blood Transplantation

A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV...

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma. Chronic lymphocytic leukemia (CLL) is the most co...

DRUG: ABBV-319

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chron...

This phase II trial studies the effect of ascorbic acid and combination chemotherapy in treating patients with lymphoma that has come back (recurrent) or does not respond to therapy (refractory), clonal cytopenia of undetermined significance and chro...

DIETARY_SUPPLEMENT: Ascorbic Acid

DRUG: Carboplatin

DRUG: Cisplatin

DRUG: Cytarabine

DRUG: Dexamethasone

DRUG: Etoposide

DRUG: Gemcitabine Hydrochloride

DRUG: Ifosfamide

OTHER: Laboratory Biomarker Analysis

DRUG: Oxaliplatin

OTHER: Placebo Administration

OTHER: Questionnaire Administration

BIOLOGICAL: Rituximab

DRUG: Decitabine

PROCEDURE: Biospecimen Collection

PROCEDURE: Core Biopsy

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Echocardiography

PROCEDURE: Positron Emission Tomography

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Central Venous Cannula Insertion

PROCEDURE: Portacath Placement

PROCEDURE: Computed Tomography

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malign...

Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell l...

BIOLOGICAL: Zilovertamab vedotin

Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma

The goal of this clinical study is to learn more about the safety and dosing of the study drugs, KITE-363 and KITE-753, in participants with relapsed and/or refractory B-cell lymphoma.

DRUG: Cyclophosphamide

DRUG: Fludarabine

BIOLOGICAL: KITE-363

BIOLOGICAL: KITE-753

A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well ...

This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma. Follicular lymphoma is a type of non-Hodgkin lymphoma or NHL. Participa...

DRUG: Odronextamab

DRUG: Rituximab

DRUG: Cyclophosphamide

DRUG: Doxorubicin

DRUG: Vincristine

DRUG: Prednisone/Prenisolone

Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma

This phase II clinical trial studies the combination of mosunetuzumab and polatuzumab vedotin in order to see how well it works in patients with untreated follicular lymphoma. Mosunetuzumab is an antibody that has been engineered to attach to two tar...

DRUG: Mosunetuzumab

DRUG: Polatuzumab vedotin

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Ly...

This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a t...

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

BIOLOGICAL: Mosunetuzumab

PROCEDURE: Positron Emission Tomography

BIOLOGICAL: Rituximab

BIOLOGICAL: Rituximab and Hyaluronidase Human

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

This is a Phase 1/2, global multicentre, open-label, single-arm, dose escalation and dose optimisation study of AZD0486 to evaluate the safety, tolerability, and efficacy of AZD0486 monotherapy in participants with R/R B ALL who have received ≥ 2 pri...

DRUG: AZD0486

Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders

The main purpose of this study is to examine the outcome of a combined bone marrow and kidney transplant from a partially matched related (haploidentical or "haplo") donor. This is a pilot study, you are being asked to participate because you have a ...

PROCEDURE: Haploidentical Bone Marrow/Kidney

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

This research study is evaluating a drug called ABL001 taken in combination with dasatinib (Sprycel®) and prednisone (a steroid) as a possible treatment for B-cell Acute Lymphoblastic Leukemia that is BCR-ABL positive (BCR-ABL+ B-ALL) or Chronic Myel...

DRUG: ABL001

DRUG: Dasatinib

DRUG: Prednisone

DRUG: Blinatumomab

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With ...

The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of zilovertamab vedotin (ZV) in combination with standard of care options for the treatment of rrDLBCL. T...

BIOLOGICAL: Zilovertamab vedotin

BIOLOGICAL: Rituximab

DRUG: Gemcitabine

DRUG: Oxaliplatin

DRUG: Bendamustine

Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte At...

The primary objective is to assess the safety and tolerability of TAB004 as monotherapy and in combination with toripalimab in subjects with selected advanced solid malignancies, including lymphoma, and to evaluate the recommended Phase 2 dose. The ...

DRUG: TAB004

DRUG: Toripalimab

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to ...

This phase 2 trial studies the side effects and best dose of tazemetostat and zanubrutinib in combination with tafasitamab and lenalidomide, and to see how well these combinations work in treating patients with large B-cell lymphoma that returned or ...

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

DRUG: Lenalidomide

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Positron Emission Tomography

OTHER: Quality-of-Life Assessment

OTHER: Questionnaire Administration

BIOLOGICAL: Tafasitamab

DRUG: Tazemetostat

DRUG: Zanubrutinib

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed ...

This phase II clinical trial tests a chemotherapy regimen (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin with or without rituximab \[DA-EPOCH+/-R\]) with the addition of targeted therapy (tafasitamab) for the trea...

DRUG: Cyclophosphamide

DRUG: Doxorubicin

DRUG: Etoposide

DRUG: Prednisone

BIOLOGICAL: Rituximab

BIOLOGICAL: Tafasitamab

DRUG: Vincristine

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

PROCEDURE: Lumbar Puncture

PROCEDURE: Biospecimen Collection

Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma

The purpose of this research study is to see if loncastuximab tesirine has any benefits at dose levels researchers found acceptable in earlier studies in patients with related forms of immune cell cancers. The researchers want to find out the effects...

DRUG: Loncastuximab tesirine 150 µg/Kg

DRUG: Loncastuximab tesirine 75µg/Kg

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Maligna...

This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX112™ in subjects with relapsed or refractory B-cell malignancies.

BIOLOGICAL: CTX112

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin L...

This phase I/II trial finds out the best dose, possible benefits and/or side effects of ALX148 in combination with rituximab and lenalidomide in treating patients with indolent and aggressive B-cell non-Hodgkin lymphoma. Immunotherapy with ALX148, ma...

DRUG: CD47 Antagonist ALX148

DRUG: Lenalidomide

BIOLOGICAL: Rituximab

Dose-escalation, Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Patients with R/r NHL and...

This is a Phase 1/1b, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of azer-cel, an allogeneic anti-CD19 CAR T, in adults with r/r B ALL and r/r B-cell NHL.

BIOLOGICAL: Azer-cel

DRUG: Fludarabine

DRUG: Cyclophosphamide

DRUG: IL-2

DRUG: Bendamustine

A Study of AZD0486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

This phase 1 study will investigate the safety, tolerability, pharmacokinetic, pharmacodynamic, and clinical activity of AZD0486, a CD19 x CD3 T-cell engaging bispecific antibody, in subjects with relapsed or refractory B-cell non-Hodgkin lymphoma (B...

DRUG: AZD0486 IV

Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin ...

Patients will receive one of two conditioning regimens (BEAM or CBV) before receiving an autologous stem cell transplant (ASCT). If patients achieve either complete, partial, or stable response following ASCT, they will receive an IV dose of Polatuzu...

DRUG: Polatuzumab vedotin

Auto Stem Cell Transplant for Lymphoma Patients

This is a phase II study of autologous transplant for patients with Hodgkin (HL) and non-Hodgkin lymphomas (NHL) including those who are HIV positive.

DRUG: Etoposide

DRUG: BCNU

DRUG: AraC

DRUG: Melphalan

PROCEDURE: Peripheral blood stem cell transplantation

BIOLOGICAL: G-CSF

DRUG: Cyclophosphamide

RADIATION: Total Body Irradiation

A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)

This is a first in human, Phase 1/2 open-label multi-center, dose escalation and expansion study to evaluate the safety, tolerability, PK, PD and efficacy of RNK05047 when administered an intravenous (IV) infusion to subjects with advanced solid tumo...

DRUG: RNK05047

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignanc...

Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This trial aims to examine ...

DRUG: Tagraxofusp

DRUG: Fludarabine

DRUG: Cytarabine

DRUG: Dexamethasone

DRUG: Vincristine

DRUG: Azacitidine

DRUG: Methotrexate

DRUG: Cytarabine IT

DRUG: Hydrocortisone

Study of SGR-1505 in Mature B-Cell Neoplasms

The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.

DRUG: SGR-1505

A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR Aft...

To learn if loncastuximab tesirine (called "lonca" in this informed consent form) can help to control large B-cell lymphoma that is relapsed or refractory after receiving CAR T-cell therapy. The safety and possible effects of the study therapy will a...

DRUG: Loncastuximab Tesirine

Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (h...

This study will determine the safety and efficacy of moving to a second-generation manufacturing process using the CliniMACS Prodigy platform to manufacture huCART19 cells for patients with B cell Acute Lymphoblastic Leukemia (B-ALL).

BIOLOGICAL: Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells (huCART19)

Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patient...

This open-label, single arm phase 1/1b trial aims to determine the safety and tolerability of anti-CD19 and anti-CD22 chimeric antigen receptor-expressing (CAR) T cells (CD19x22 CAR T) in adolescents and adults with relapsed/refractory (R/R) B-cell N...

DRUG: CD19x22 CAR T Cells

Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Dis...

This is a treatment guideline for an unrelated umbilical cord blood transplant (UCBT) using a myeloablative preparative regimen for the treatment of hematological diseases, including, but not limited to acute leukemias. The myeloablative preparative ...

DRUG: Fludarabine

DRUG: Cyclophosphamide

RADIATION: Total Body Irradiation

DRUG: Cyclosporine A

DRUG: Mycophenylate mofetil

BIOLOGICAL: Umbilical cord blood

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for th...

This phase I trial studies the safety and feasibility of cytomegalovirus (CMV) specific CD19-chimeric antigen receptor (CAR) T cells in combination with the CMV-modified vaccinia Ankara (MVA) triplex vaccine following lymphodepletion in treating pati...

BIOLOGICAL: Anti-CD19-CAR CMV-specific T-lymphocytes

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

PROCEDURE: Leukapheresis

PROCEDURE: Lymphodepletion Therapy

PROCEDURE: Magnetic Resonance Imaging

BIOLOGICAL: Multi-peptide CMV-Modified Vaccinia Ankara Vaccine

PROCEDURE: Positron Emission Tomography

PROCEDURE: X-Ray Imaging

Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With ...

This phase II trial compares mosunetuzumab to the usual treatment (rituximab) for improving survival in patients with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). Rituximab and mosunetuzumab are monoclonal antibodies. They bind to a prote...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

OTHER: Fludeoxyglucose F-18

BIOLOGICAL: Mosunetuzumab

PROCEDURE: Positron Emission Tomography

BIOLOGICAL: Rituximab

BIOLOGICAL: Rituximab and Hyaluronidase Human

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR...

Background: Aggressive B-cell lymphomas can be cured but people with disease that resists treatment or that returns after treatment have poor outcomes with standard therapies. Indolent B-cell lymphomas are generally incurable with standard therapy a...

BIOLOGICAL: obinutuzumab

DRUG: prednisone

DRUG: Revlimid

BIOLOGICAL: Polatuzumab

DRUG: ibrutinib

DRUG: venetoclax

Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Di...

This early phase I trial investigates how well duvelisib exposure before CAR-T cell manufacturing works to enhance immune profiles of T cells in patients with diffuse large B-cell lymphoma that has come back (recurrent) or does not respond to treatme...

DRUG: Duvelisib

BIOLOGICAL: Tisagenlecleucel

Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation from Chronic Ly...

This phase II trial tests whether acalabrutinib, venetoclax, and durvalumab work in treating patients with Richter transformation from chronic lymphocytic leukemia or small lymphocytic lymphoma. Richter transformation is a rare condition in which chr...

DRUG: Acalabrutinib

BIOLOGICAL: Durvalumab

DRUG: Venetoclax

Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

This research is being done to assess the effectiveness and safety of acalabrutinib combined with lisocabtagene maraleucel (liso-cel) for people with relapsed/refractory aggressive B-cell lymphoma. This research study involves the study drug acalabr...

DRUG: ACALABRUTINIB

DRUG: LISOCABTAGENE MARALEUCEL

DRUG: Lymphodepleting chemotherapy

A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R...

This is a Phase 1, open-label, multicenter study. This will be the first-in-human clinical study for ONO-7018 and will be conducted in two phases: a Dose Escalation Phase (Part 1) and a Dose Expansion Phase (Part 2).

DRUG: ONO-7018

Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas

The purpose of the study is to establish the safety and efficacy of zanubrutinib in combination with rituximab for people with untreated B-cell lymphomas (marginal zone lymphoma and follicular lymphomas).

DRUG: Zanubrutinib

DRUG: Rituximab

Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma

This phase Ib/II trial studies the side effects and efficacy of maintenance acalabrutinib following cellular therapy in treating patients with large B-cell lymphoma at very high risk of the cancer coming back. Acalabrutinib is a small molecular inhib...

DRUG: Acalabrutinib

Pirtobrutinib and Venetoclax with MRD Detection for Previously Untreated Chronic Lymphocytic Leukemi...

This phase II trial studies how well pirtobrutinib and venetoclax work in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. This study also seeks to adopt a blood test which shows a small number of cancer cells in the...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

PROCEDURE: Magnetic Resonance Imaging

DRUG: Pirtobrutinib

PROCEDURE: Positron Emission Tomography

DRUG: Venetoclax

PROCEDURE: Echocardiography

PROCEDURE: Multigated Acquisition Scan

PROCEDURE: Biopsy

Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People Wit...

This study will find out whether people with CLL or SLL who have received treatment with venetoclax, either alone or in combination with another drug, and who are found to be MRD-negative, can stop treatment with venetoclax and remain off-treatment f...

DRUG: Venetoclax monotherapy

DRUG: Venetoclax with anti CD20 monoclonal antibody

A Safety Study of SGN-35C in Adults With Advanced Cancers

This clinical trial is studying lymphoma. Lymphoma is a cancer that starts in the blood cells that fight infection. There are several types of lymphoma. This study will enroll people who have classical Hodgkin lymphoma (cHL), peripheral T cell lympho...

DRUG: SGN-35C

Avo in R/R and Previously Untreated MCL

This research study is evaluating the combination of three drugs - acalabrutinib, venetoclax, and obinutuzumab - as a possible treatment for relapsed or refractory and untreated mantle cell lymphoma (MCL). The names of the study drugs involved in th...

DRUG: Acalabrutinib

DRUG: Venetoclax

DRUG: Obinutuzumab

Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refr...

This phase II trial studies how well inotuzumab ozogamicin and blinatumomab work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly diagnosed, has come back, or does not respond to treatment. Immunotherapy wi...

BIOLOGICAL: Blinatumomab

BIOLOGICAL: Inotuzumab Ozogamicin

UCD19 CAR T Therapy in Adults with B-ALL and MRD Positivity in CR1

This open-label, single arm Phase I trial aims to determine the safety and tolerability of anti-CD19 chimeric antigen receptor-expressing (CAR) T cells (UCD19 CAR T) in adults B-ALL that are in first complete remission with minimal residual disease (...

DRUG: CD19 Directed CAR T Cell

Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, S...

This phase II trial studies how well atezolizumab, obinutuzumab, and venetoclax work in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma or Richter syndrome that has come back (recurrent) or does not respond to treatm...

DRUG: Atezolizumab

OTHER: Laboratory Biomarker Analysis

BIOLOGICAL: Obinutuzumab

DRUG: Venetoclax

Zanubrutinib in Combination with R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Ly...

This phase Ib trial seeks to find out the best dose and possible side effects and/or benefits of zanubrutinib in combination with the R-PolaCHP in treating patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Zanubrutinib is designed ...

DRUG: Cyclophosphamide

DRUG: Doxorubicin Hydrochloride

DRUG: Prednisone

BIOLOGICAL: Rituximab

DRUG: Vincristine Sulfate

DRUG: Zanubrutinib

CD22 Redirected Autologous T Cells for ALL

This is a pilot study to determine the feasibility and safety of a single dose of autologous T cells expressing CD22 chimeric antigen receptors expressing tandem TCR-ζ and 4-1BB signaling domains (CART22/CART22-65s cells) in pediatric and young adult...

BIOLOGICAL: Cohort 1

BIOLOGICAL: Cohorts 2

BIOLOGICAL: Cohort 3

A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient S...

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Classic Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma. The purpose of this study is to assess th...

DRUG: Epcoritamab

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD2...

This is a Phase I/II study designed to evaluate if experimental T cell engaging antibody targeting CD20 AZD5492 is safe, tolerable and efficacious in participants with Relapsed or Refractory B-Cell Malignancies.

DRUG: AZD5492

Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly ...

This phase I/II trial tests the safety and effectiveness of glofitamab (with obinutuzumab pretreatment), venetoclax, and lenalidomide in treating patients with newly diagnosed, high risk mantle cell lymphoma. Glofitamab and obinutuzumab are monoclona...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

BIOLOGICAL: Glofitamab

DRUG: Lenalidomide

BIOLOGICAL: Obinutuzumab

PROCEDURE: Positron Emission Tomography

DRUG: Venetoclax

Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-...

Bruton's tyrosine kinase inhibitors (BTKi), anti-CD20 antibodies, and the B cell lymphoma 2 inhibitor (BCL-2i) venetoclax are drug classes used to treat patients with chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL). Anti-CD20 therap...

DRUG: Zanubrutinib Pill

DRUG: Venetoclax Pill

DRUG: Obinutuzumab Injection

Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignan...

This phase I trial studies the safety of transplantation with a haploidentical donor peripheral blood stem cell graft depleted of TCRαβ+ cells and CD19+ cells in conjunction with the immunomodulating drug, Zoledronate, given in the post-transplant pe...

PROCEDURE: TCRαβ+/CD19+ depleted Haploidentical HSCT

DRUG: Zoledronate

Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL

The study will measure the safety, tolerability, and efficacy with acalabrutinib in combination with rituximab in treatment-naïve elderly and/or frail patients with diffuse large B-cell lymphoma (DLBCL), who are otherwise unsuitable for standard fron...

DRUG: Acalabrutinib

BIOLOGICAL: Rituximab

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

This is a phase II, open-label, prospective study of T cell receptor alpha/beta depletion (α/β TCD) peripheral blood stem cell (PBSC) transplantation for children and adults with hematological malignancies

DRUG: Fludarabine

DRUG: Busulfan

DRUG: Melphalan

DRUG: Rituximab

DRUG: Levetiracetam

Acalabrutinib with or Without Obinutuzumab in Treating Patients with Early-Stage Chronic Lymphocytic...

This phase II trials studies how well acalabrutinib with or without obinutuzumab works in treating patients with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma. Acalabrutinib may stop the growth of cancer cells by blocking som...

DRUG: Acalabrutinib

OTHER: Laboratory Biomarker Analysis

BIOLOGICAL: Obinutuzumab

OTHER: Patient Observation

OTHER: Quality-of-Life Assessment

AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin...

AB-101 is an off-the shelf, allogeneic cell product made of "natural killer" cells, also called NK cells. White blood cells are part of the immune system and NK cells are a type of white blood cell that are known to kill cancer cells. This clinical ...

DRUG: AB-101

DRUG: Rituximab

DRUG: Interleukin-2

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: Bendamustine

Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Che...

The safety run-in part of the study aims to evaluate the safety and tolerability of blinatumomab alternating with low-intensity chemotherapy. The phase 3 part of the study aims to compare event-free survival (EFS) and overall survival (OS) of partici...

DRUG: Blinatumomab

DRUG: Low-intensity chemotherapy regimen

DRUG: SOC chemotherapy regimen

Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma

This phase II trial tests how well nemtabrutinib works with rituximab for the treatment of patients with mantle cell lymphoma. Nemtabrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Biopsy

DRUG: Nemtabrutinib

PROCEDURE: Positron Emission Tomography and Computed Tomography Scan

BIOLOGICAL: Rituximab

Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-A...

This is a Phase 2 Study is to determine the efficacy and safety rate of B-Cell Acute Lymphoblastic Leukemia (B-ALL) participants in remission with minimal residual disease (MRD) after KTE-X19 CAR T-cell therapy

DRUG: Tecartus

Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab ...

To learn if cyclophosphamide, vincristine, and dexamethasone (called mini hyper-CVD) in combination with intrathecal (delivered into the spine) chemotherapy (methotrexate, hydrocortisone, cytarabine) and compressed rituximab, blinatumomab, and inotuz...

DRUG: Cyclophosphamide

DRUG: Vincristine

DRUG: Blinatumomab

DRUG: Methotrexate

DRUG: Cytarabine

DRUG: Mercaptopurine

DRUG: Prednisone

DRUG: Pegfilgrastim

DRUG: Inotuzumab ozogamicin

DRUG: Rituximab

DRUG: Dexamethasone

CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma

This phase I trial tests the safety, side effects and best dose of CC-99282 with rituximab for the treatment of patients who have received chimeric antigen receptor (CAR) T cell therapy for non-Hodgkins lymphoma and in whom have had a sub-optimal res...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

DRUG: Golcadomide

PROCEDURE: Positron Emission Tomography

BIOLOGICAL: Rituximab

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Le...

The study is a global, multi-center safety and efficacy trial of epcoritamab, an antibody also known as EPKINLY™ and GEN3013 (DuoBody®-CD3xCD20). Epcoritamab will either be studied as: * Monotherapy, or * Combination therapy: * epcoritamab + vene...

BIOLOGICAL: Epcoritamab

DRUG: rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone

DRUG: Venetoclax

BIOLOGICAL: Epcoritamab

DRUG: Lenalidomide

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell...

This is a Phase Ib study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 in pediatric patients with relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B ALL) an...

BIOLOGICAL: AUTO1

A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of Hi...

This study is planned as a single arm clinical trial of tazemetostat in combination with bendamustine and rituximab with both a phase I and phase II component. All patients will receive tazemetostat twice daily on days 1-28 in combination with bendam...

DRUG: Bendamustine

DRUG: Rituximab

DRUG: Tazemetostat

Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy

The purpose of the study is to assess the safety and efficacy of once daily itacitinib oral administration in participants with diffuse large B-cell lymphoma (DLBCL) who will receive CAR-T cell therapy with axicabtagene ciloleucel (axi-cel).

DRUG: Itacitinib

BIOLOGICAL: Chimeric antigen receptor (CAR) T-cell therapy

A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)

The goal of this multicenter study is to test JNJ-90009530 in Relapsed or Refractory Non-Hodgkin Lymphoma Patients. The main questions the study aims to answer are: * can a dose of JNJ-90009530 be determined that is safe and well tolerated by patien...

DRUG: JNJ-90009530

Emapalumab Prevention of CAR-T Cell Associated Toxicities

This research study involves assessing the impact of emapalumab as preventative management of CAR-T related cytokine release syndrome in participants with Non-Hodgkin's lymphoma (NHL). The research study involves the following study interventions: ...

DRUG: Emapalumab

DRUG: Cyclophosphamide

DRUG: Fludarabine Phosphate

DRUG: Axicabtagene Ciloleucel

TTI-622 in Combination with Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large ...

This phase II trial tests the safety, side effects, and best dose of TTI-621 (closed to enrollment) or TTI-622 in combination with pembrolizumab in treating patients with diffuse large B-cell lymphoma that has come back after a period of improvement ...

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

DRUG: Ontorpacept

BIOLOGICAL: Pembrolizumab

PROCEDURE: Positron Emission Tomography

DRUG: Maplirpacept

PROCEDURE: Biopsy

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

This research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory Non-Hodgkin Lymphoma and to understand the side effects when treated with CD79b-19 CAR T cells. This research study involves the study drugs:...

DRUG: CD79b-19 CAR T cells

DRUG: Cyclophosphamide

DRUG: Fludarabine

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Media...

This phase III trial compares the effects of nivolumab with chemo-immunotherapy versus chemo-immunotherapy alone in treating patients with newly diagnosed primary mediastinal B-cell lymphoma (PMBCL). Immunotherapy with monoclonal antibodies, such as ...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

DRUG: Cyclophosphamide

DRUG: Doxorubicin Hydrochloride

PROCEDURE: Echocardiography

DRUG: Etoposide Phosphate

BIOLOGICAL: Filgrastim

PROCEDURE: Lumbar Puncture

BIOLOGICAL: Nivolumab

BIOLOGICAL: Pegfilgrastim

PROCEDURE: Positron Emission Tomography

DRUG: Prednisolone

DRUG: Prednisone

RADIATION: Radiation Therapy

BIOLOGICAL: Rituximab

BIOLOGICAL: Rituximab and Hyaluronidase Human

DRUG: Vincristine Sulfate

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.

DRUG: Docirbrutinib

CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lym...

CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after lymphodepletion consisting of cyclophosphamide and fludarabine.

GENETIC: CB-010

DRUG: Cyclophosphamide

DRUG: Fludarabine

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)

DRUG: BGB-16673

FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)

This is a phase 1 study of FT522 administered with rituximab in participants with relapsed/refractory B-cell lymphoma (R/R BCL). The primary objectives of the study are to evaluate the safety and tolerability of FT522 in combination with rituximab, a...

DRUG: FT522

DRUG: Rituximab

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: Bendamustine

NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large...

This study will evaluate the safety and efficacy of NKTR-255 following CD19-directed chimeric antigen (CAR)-T cell therapy in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL). NKTR-255 is an investigational IL-15 receptor agon...

DRUG: NKTR-255 at 1.5 µg/kg

DRUG: NKTR-255 at 3.0 μg/kg

DRUG: NKTR-255 at 3.0/6.0 μg/kg

OTHER: Placebo Comparator

Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma

The purpose of this study is to determine how effective and safe the combination of glofitamab and obinutuzumab is in treating patients with Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) who have not received other treatments for their ly...

DRUG: Obinutuzumab

DRUG: Glofitamab

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukem...

This phase II trial studies the side effects and how well combination chemotherapy works in treating patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, Burkitt lymphoma/leukemia, or double-hit lymphoma/leukemia that has come back or ...

DRUG: Bortezomib

DRUG: Clofarabine

DRUG: Cyclophosphamide

DRUG: Dexamethasone

DRUG: Etoposide

BIOLOGICAL: Ofatumumab

BIOLOGICAL: Pegfilgrastim

BIOLOGICAL: Rituximab

DRUG: Vincristine Sulfate Liposome

Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma

This phase I trial tests the safety, side effects, best dose and effectiveness of lenalidomide when added to nivolumab and the usual drugs (rituximab and methotrexate) in patients with primary central nervous system (CNS) lymphoma. Lenalidomide may s...

PROCEDURE: Bone Marrow Aspiration and Biopsy

PROCEDURE: Computed Tomography

PROCEDURE: Echocardiography

DRUG: Lenalidomide

PROCEDURE: Lumbar Puncture

PROCEDURE: Magnetic Resonance Imaging

DRUG: Methotrexate

BIOLOGICAL: Nivolumab

PROCEDURE: Positron Emission Tomography

BIOLOGICAL: Rituximab

PROCEDURE: Ultrasound Imaging

Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma

This phase 1 pilot study examines the feasibility and safety of mosunetuzumab after autologous stem cell transplant for patients with aggressive B cell lymphomas. Mosunetuzumab is an antibody that has been engineered to attach to two target cells in ...

DRUG: Mosunetuzumab

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed o...

This phase Ib trial studies the effects of venetoclax in combination with dasatinib, prednisone, rituximab and blinatumomab in treating patients with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL) that is newly diagnosed or that ...

DRUG: Dasatinib

DRUG: Methotrexate

DRUG: Prednisone

BIOLOGICAL: Rituximab

DRUG: Venetoclax

BIOLOGICAL: Blinatumomab

PROCEDURE: Bone Marrow Aspiration and Biopsy

PROCEDURE: Lumbar Puncture

PROCEDURE: Biospecimen Collection

Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic ...

This phase II trial tests how well tafasitamab and zanubrutinib works in treating patients with newly diagnosed chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Tafasitamab is a monoclonal antibody that may interfere with the abil...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

BIOLOGICAL: Tafasitamab

DRUG: Zanubrutinib

A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indo...

Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab with or without Acalabrutinib in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That has Relapsed or is Refractory to Rituximab

BIOLOGICAL: BI-1206

BIOLOGICAL: Rituximab

BIOLOGICAL: Acalabrutinib

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through th...

Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood cells). The purpose of this study is to assess the safety, pharmacokinetics, and preliminary efficacy of ABBV-101 in adult partici...

DRUG: ABBV-101

Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lym...

This phase II trial tests how well tafasitamab, lenalidomide and venetoclax work in treating patients with mantle cell lymphoma that has come back (after a period of improvement) (relapsed) or that has not responded to previous treatment (refractory)...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

DRUG: Lenalidomide

PROCEDURE: Lumbar Puncture

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Positron Emission Tomography

BIOLOGICAL: Tafasitamab

DRUG: Venetoclax

Study of Oral MRT-2359 in Selected Cancer Patients

This Phase 1/2, open-label, multicenter study is conducted in patients with previously treated selected solid tumors, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), high-grade neuroendocrine cancer of any primary site, d...

DRUG: Oral MRT-2359

Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients Wit...

This study will assess the safety, efficacy, and feasibility of ⍺/β CD3+ T-cell and CD19+ B-cell depletion in allogeneic stem cell transplantation in patients with acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), juvenile myelomonocyti...

DEVICE: Miltenyi CliniMACS Prodigy ® system

A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Ly...

To learn if response-adapted, ultra-low dose radiation therapy can help to control MZL. This means participates first receive lower does of radiation therapy and then, based on how the disease responds, may receive higher doses after that.

RADIATION: Ultra Low Dose 4 Gy Radiation

BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL

A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

BIOLOGICAL: BAFFR-CAR T cells

Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or...

This phase II trial studies how well zanubrutinib and rituximab work in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma for which the patient has not received treatment in the past (previously untreated). Zanubrutini...

BIOLOGICAL: Rituximab

DRUG: Zanubrutinib

Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refracto...

This phase II trial investigates the side effects of CD19 chimeric antigen receptor (CAR) T cells and acalabrutinib, and to see how well they work in treating patients with mantle cell lymphoma that has come back (relapsed) or does not respond to tre...

DRUG: Acalabrutinib

BIOLOGICAL: CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes

Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome

This phase II trial tests how well zanubrutinib and lisocabtagene maraleucel (liso-cel) work together in treating patients with Richter's syndrome. Richter's syndrome occurs when chronic lymphocytic leukemia and/or small lymphocytic leukemia transfor...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

DRUG: Cyclophosphamide

DRUG: Fludarabine

PROCEDURE: Leukapheresis

BIOLOGICAL: Lisocabtagene Maraleucel

PROCEDURE: Lymph Node Biopsy

PROCEDURE: Positron Emission Tomography

DRUG: Zanubrutinib

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell ...

Background: B-cell lymphoma is a cancer of white blood cells found in the lymph nodes. It affects the system that fights infections and disease. Researchers want to learn how certain drugs work together to treat B-cell lymphomas. The drugs are venet...

DRUG: Venetoclax

DRUG: Ibrutinib

DRUG: Prednisone

BIOLOGICAL: Obinutuzumab

DRUG: Revlimid (lenalidomide)

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants with Relapsed/Ref...

The purpose of this study is to evaluate the safety and preliminary efficacy of ATA3219 in participants with relapsed/refractory (R/R) B-cell non-Hodgkin Lymphoma (NHL).

DRUG: ATA3219

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL)

Background: Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are blood cancers that affect certain white blood cells. Advanced forms of these diseases are difficult to treat. CD19 is a protein often found on the surfaces of th...

BIOLOGICAL: Autologous HuCD19 ( Anti-CD19)CAR T cells

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: Rituximab

A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp ...

This is a phase I/II, open-label, dose-escalation study designed to evaluate the safety, tolerability, and efficacy of englumafusp alfa (RO7227166) in participants with relapsed/refractory Non-Hodgkin's Lymphoma (r/r NHL). Englumafusp alfa will be ad...

DRUG: Englumafusp alfa

DRUG: Obinutuzumab

DRUG: Glofitamab

DRUG: Tocilizumab

A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas

This is a clinical trial to evaluate the feasibility and safety of giving tazemetostat followed by standard of care CAR T cell infusion in previously treated diffuse large b-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (M...

DRUG: Tazemetostat Pill

Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lym...

The proposed study is an open-label, single arm phase II study of venetoclax in combination with rituximab in patients over the age of 60 with previously untreated mantle cell lymphoma. The primary objective of the trial is to determine whether the c...

DRUG: Venetoclax Oral Tablet [Venclexta]

A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Ther...

To learn about the safety of a drug called axicabtagene ciloleucel given in combination with radiation therapy to patients with relapsed/refractory FL.

DRUG: Axicabtagene Ciloleucel

DRUG: Cyclophosphamide

DRUG: Fludarabine phosphate

DRUG: Prednisone

DRUG: Diphenhydramine

DRUG: Acetaminophen

Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicu...

The purpose of this research is to see if Loncastuximab Tesirine in combination with Rituximab will result in higher complete response rate when given to treat follicular lymphoma.

DRUG: Loncastuximab tesirine

DRUG: Rituximab

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Pa...

To learn if the combination of pirtobrutinib (also called LOXO-305) and venetoclax can help to control mantle cell lymphoma (MCL) that is relapsed (has come back) or refractory (has not responded to therapy).

DRUG: Pirtobrutinib

DRUG: Venetoclax

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

This clinical trial is studying the safety and potential anti-tumor activity of an investigational drug called ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma to determine if ARV-393 may be a possible treatment ...

DRUG: ARV-393

Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Ly...

This phase II trial is to evaluate the effects of acalabrutinib in combination with venetoclax in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma that does not respond to treatment (refractory) or that has come back ...

DRUG: Acalabrutinib

DRUG: Venetoclax

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

PROCEDURE: Magnetic Resonance Imaging

CAR-T Followed by Bispecific Antibodies

The research study is being conducted to test the safety and effectiveness of the experimental drug mosunetuzumab (Cohort 1) or obinutuzumab and glofitamab (Cohort 2) when given after CAR (genetically modified) T cells. The study is for patients who ...

DRUG: mosunetuzumab

DRUG: glofitamab

DRUG: obinutuzumab

Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas

This is a Phase 1/2a open-label, multicenter, dose escalation and dose expansion trial in which IMT-009 will be administered by the intravenous (IV) route to participants with solid tumors or lymphomas. The main goals of this study are to: * Find t...

DRUG: IMT-009

COMBINATION_PRODUCT: Fruquintinib

DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects ...

This is a Phase 2b, randomized, open label study to assess the safety and efficacy of DPX-Survivac and pembrolizumab, with and without low-dose cyclophosphamide (CPA) in subjects with relapsed or refractory DLBCL.

DRUG: DPX-Survivac

DRUG: Pembrolizumab

DRUG: CPA

Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chem...

Subjects with relapsed large cell lymphoma will receive 3 cycles of combination therapy consisting of GDP and epcoritamab. Each cycle will last 21 days. GDP consists of gemcitabine 1000 mg/m2 IV on Days 1 and 8, cisplatin 75 mg/m2 IV on Day 1, and de...

PROCEDURE: AutoSCT OR CAR T-cell Therapy

DRUG: GDP

DRUG: Epcoritamab

An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lympho...

This phase I trial studies the side effects and best dose of venetoclax when given together with lenalidomide and rituximab hyaluronidase in treating patients with follicular lymphoma and marginal zone lymphoma that has come back after treatment (rel...

DRUG: Venetoclax

DRUG: Lenalidomide

BIOLOGICAL: Rituximab

BIOLOGICAL: Rituximab and Hyaluronidase Human

Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies

This is an open-label, multicenter, phase I study, which primary objective is to characterize the safety and tolerability of PIT565 and to identify maximal tolerated doses (MTDs) and/or recommended doses (RDs), schedule and route of administration in...

BIOLOGICAL: PIT565

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

This clinical trial is evaluating a drug called AC676 in participants with Relapsed/Refractory B-cell Malignancies. The main goals of the study are to: * Identify the recommended dose of AC676 that can be given safely to participants * Evaluate the ...

DRUG: AC676

A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab...

The purpose of this study is to learn about the effects of two study medicines (maplirpacept \[PF-07901801\] and glofitamab) when given together for the treatment of diffuse large B-cell lymphoma (DLBCL) that is relapsed or is refractory. Relapsed me...

DRUG: maplirpacept (PF-07901801)

DRUG: Glofitamab

DRUG: Obinutuzumab

Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma

The goal of this study is to learn about the safety and effectiveness of the combination of tazemetostat pills in combination with mosunetuzumab injections for people with follicular lymphoma who haven't received treatment before. The investigators h...

DRUG: Mosunetuzumab

DRUG: Tazemetostat Pill

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymph...

This is a Phase 1b study consisting of 2 parts: a dose escalation (Part 1) of CC-220 or CC-99282 added to the standard R-CHOP-21 regimen for first-line treatment of a-BCL. The dose escalation (Part 1) will consist of 2 parallel arms in combination wi...

DRUG: CC-220

DRUG: Rituximab

DRUG: Cyclophosphamide

DRUG: Doxorubicin

DRUG: Vincristine

DRUG: Prednisone

DRUG: CC-99282

DRUG: Polatuzumab vedotin

DRUG: Rituximab

huCART19-IL18 in CD19+ Cancers

The purpose of this study is to find the maximum dose of huCART19-IL18 cells that is safe for use in humans with CD19+ cancers.

BIOLOGICAL: huCART19-IL18

Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patie...

This is a pilot study; patients will receive 131-I apamistamab prior to CAR T-cell infusion in order to determine the maximum tolerated dose of 131-I apamistamab is exceeded at 75 mCi, and if so, to assess the safety of a step-down dose of 50 mCi.

DRUG: 131-I Apamistamab

BIOLOGICAL: CAR T-cell

Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Ste...

The goal of this phase II clinical study is to learn about the safety of inotuzumab ozogamicin when given with fludarabine, with or without bendamustine, melphalan, and rituximab before and after a stem cell transplant. Researchers also want to learn...

PROCEDURE: Allogeneic Bone Marrow Transplantation

DRUG: Bendamustine

BIOLOGICAL: Filgrastim-sndz

DRUG: Fludarabine

BIOLOGICAL: Inotuzumab Ozogamicin

DRUG: Melphalan

PROCEDURE: Peripheral Blood Stem Cell Transplantation

BIOLOGICAL: Rituximab

DRUG: Tacrolimus

A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants...

This is a Phase 1 dose-escalation study of PRT2527, a potent and highly selective cyclin-dependent kinase (CDK) 9 inhibitor, in participants with select relapsed or refractory (R/R) hematologic malignancies. The purpose of this study is to evaluate t...

DRUG: PRT2527

DRUG: Zanubrutinib

DRUG: Venetoclax

BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL

A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)

BIOLOGICAL: BAFFR-CAR T cells

A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma

This is a Phase Ib multicenter, open-label study of JNJ-90014496, an autologous bi-specific chimeric antigen receptor (CAR) T-cell therapy, targeting both cluster of differentiation (CD) CD19 and CD20 for the treatment of adult participants with B-Ce...

BIOLOGICAL: JNJ-90014496

A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas

The Phase 1 part of the study is a dose escalation of STP938 as monotherapy. The Phase 2 part of the study is cohort expansion of STP938 as a monotherapy in 5 different B and T cell lymphomas.

DRUG: STP938

Study of IMPT-314 in R/R Aggressive B-cell NHL

This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of IMPT-314, a bispecific chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive B-cell NHL. Three co...

DRUG: IMPT-314

A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies

This study evaluates the safety, pharmacokinetics, and efficacy of BP1002 (L-Bcl-2) antisense oligonucleotide in patients with advanced lymphoid malignancies. Up to 12 evaluable patients with a diagnosis of relapsed or refractory lymphoid malignancie...

DRUG: L-Bcl-2 antisense oligonucleotide

A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas

First-in-human, open-label, sequential dose escalation and expansion study of CPI-0209 in patients with advanced solid tumors and lymphomas. CPI-0209 is a small molecule inhibitor of EZH2.

DRUG: CPI-0209

Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL

This is a phase 2, single-arm, open-label study to evaluate the safety and efficacy of comprehensive bridging radiation therapy prior to CD19 CAR T-cell therapy for large B-cell lymphoma patients with bulky disease, defined as any lesion ≥5 cm.

RADIATION: Comprehensive Ablative Bridging Irradiation (CABI)

BIOLOGICAL: Chimeric Antigen Receptor T-Cell Therapy

UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL

This phase I/II trial will investigate a new CD19 directed CAR-T therapy manufactured locally with the goals to expedite infusion to wider patient inclusion that includes those who were previously excluded, such as pediatric patients with B-cell NHL ...

DRUG: CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells

Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients with Relapsed or Refractory Grad...

This phase II trial tests how well mosunetuzumab and polatuzumab vedotin works in treating patients with grade 1-3a follicular lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refra...

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

PROCEDURE: Magnetic Resonance Imaging

BIOLOGICAL: Mosunetuzumab

DRUG: Polatuzumab Vedotin

PROCEDURE: Positron Emission Tomography

OTHER: Questionnaire Administration

Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemo...

This phase II trial compares the combination of inotuzumab ozogamicin and chemotherapy to the usual chemotherapy in treating patients with B-cell acute lymphoblastic leukemia or B-cell lymphoblastic lymphoma. Inotuzumab ozogamicin is a monoclonal ant...

DRUG: Cyclophosphamide

DRUG: Vincristine

DRUG: Dexamethasone

BIOLOGICAL: Inotuzumab Ozogamicin

DRUG: Methotrexate

DRUG: Cytarabine

DRUG: Methylprednisolone

BIOLOGICAL: Rituximab

DRUG: Prednisone

DRUG: Mercaptopurine

DRUG: Doxorubicin

Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL

This is a phase 2, open-label, randomized, multicenter clinical trial in patients with relapsed/refractory mantle cell lymphoma (R/R MCL) who meet the criteria for standard-of-care FDA label for CD19 CAR T-cell therapy with brexucabtagene autoleucel ...

DRUG: Pirtobrutinib

DRUG: Brexucabtagene Autoleucel

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Par...

The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with BGB-16673 in combination with other agents in participants with relapsed or refractory (R/R) B-cell malignancies. This stu...

DRUG: BGB-16673

DRUG: sonrotoclax

DRUG: Zanubrutinib

DALY II USA/ MB-CART2019.1 for DLBCL

DALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory diffuse large B cell lymphoma (DLBCL) after rece...

BIOLOGICAL: zamtocabtagene autoleucel (MB-CART2019.1)

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: Bendamustine

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination Wit...

The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin, glofitamab, or mosunetuzumab, and to identify the maximum tolerated dose (MTD) and/or recommended do...

DRUG: Loncastuximab Tesirine

DRUG: Polatuzumab Vedotin

DRUG: Glofitamab

DRUG: Mosunetuzumab

DRUG: Obinutuzumab

A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic...

This is an open label, multicenter, phase 1/2 dose evaluation and cohort expansion study evaluating the safety and efficacy of CTX131 in subjects with Relapsed/Refractory Hematologic Malignancies

BIOLOGICAL: CTX131

Acalabrutinib in Combination with Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Ch...

This phase II trial tests whether acalabrutinib in combination with venetoclax or obinutuzumab works to shrink tumors in patients with treatment-naive chronic lymphocytic leukemia . Acalabrutinib is also an inhibitor that works in the body to block t...

DRUG: Acalabrutinib

BIOLOGICAL: Obinutuzumab

DRUG: Venetoclax

Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Y...

This phase I trial studies the best dose and side effects of CD19/CD22 chimeric antigen receptor (CAR) T cells when given together with chemotherapy, and to see how well they work in treating children or young adults with CD19 positive B acute lympho...

BIOLOGICAL: Chimeric Antigen Receptor T-Cell Therapy

DRUG: Cyclophosphamide

DRUG: Fludarabine Phosphate

OTHER: Laboratory Biomarker Analysis

OTHER: Questionnaire Administration

Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL

This is a phase I/II study to evaluate the feasibility, safety and preliminary antitumor efficacy of rapcabtagene autoleucel (also known as YTB323). Rapcabtagene autoleucel will be investigated in combination with ibrutinib in chronic lymphocytic leu...

BIOLOGICAL: Rapcabtagene autoleucel single agent

DRUG: Ibrutinib

Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Conso...

To learn about the safety of giving the drug brexucabtagene autoleucel to participants with relapsed/refractory B-cell ALL after treatment with inotuzumab ozogamicin, blinatumomab, and either hyper-CVAD or mini-hyper-CVD. Also, to learn if giving bre...

DRUG: Blinatumomab

DRUG: Inotuzumab Ozogamicin

DRUG: Hyper-CVAD

DRUG: Mini-hyper-CVD

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination with Cem...

A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral ONM-501 as monotherapy ...

DRUG: ONM-501

DRUG: Cemiplimab

First-in-Human (FIH) Trial of 1A46 in Subjects With Advanced CD20 and/or CD19 Positive B-cell Hemato...

This study will evaluate the safety and efficacy of 1A46 in adult patients with advanced CD20 and/or CD19 positive B-cell non-Hodgkin's lymphoma (NHL) or acute lymphoblastic leukemia (ALL).

DRUG: 1A46 Injection

CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL

This study will evaluate the safety and tolerability of administering a novel bispecific CD19/CD22-directed CAR T cell product (CD19x22) for the treatment of relapsed or refractory pediatric B-ALL.

BIOLOGICAL: CD19x22 CAR T

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

A multi-center, open-label, randomized, phase Ib study to evaluate the pharmacokinetics (PK) of HQP1351 and to determine the recommended phase 2 dose (RP2D) of HQP1351 in subjects with CML chronic phase (CP), accelerated phase (AP), or blast phase (B...

DRUG: Ascentage Pharma HQP1351 bioavailable inhibitor

DRUG: Blinatumomab

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Be...

One of the ways that cancer grows and spreads is by avoiding the immune system.NK cells are immune cells that kill cancer cells, but are often malfunctioning in people with colorectal cancer and blood cancers. A safe way to give people with colorecta...

DRUG: Vactosertib

DRUG: Fludarabine Phosphate

DRUG: Cyclophosphamide

DRUG: IL-2

DRUG: Natural Killer Cells

Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL

This research study is studying a combination of drugs as a possible treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The names of the study drugs involved in this study are: * obinutuzumab * venetoclax * acalab...

DRUG: Venetoclax

DRUG: Obinutuzumab

DRUG: Acalabrutinib

Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to C...

This phase II trial tests how well pirtobrutinib (LOXO-305) and venetoclax works in treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that remains despite treatment (resistant) with covalent bruton tyrosine...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

DRUG: Pirtobrutinib

DRUG: Venetoclax

A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory...

This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/r FL or MZL. The study will be conducted in compliance with the International Council on Harmonisati...

DRUG: Fludarabine

DRUG: Cyclophosphamide

DRUG: JCAR017

A Trial to Learn if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab ...

This study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on participants who have one of two types of cancer: follicular lymphoma (FL) or marginal zone lymp...

DRUG: Odronextamab

DRUG: Lenalidomide

DRUG: Rituximab

A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participan...

The purpose of this study is to characterize safety and to determine the putative recommended Phase 2 dose(s) (RP2D\[s\]), optimal dosing schedule(s) and route(s) of administration of JNJ-80948543 in Part A (Dose Escalation) and to further characteri...

DRUG: JNJ-80948543

A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenou...

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). This study will assess how safe and effective epcoritamab plus lenalidomide (E-Len) is compared to rituximab plus gem...

DRUG: Epcoritamab

DRUG: Rituximab

DRUG: Lenalidomide

DRUG: Oxaliplatin

DRUG: Gemcitabine

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma...

A Phase 3, randomized, 2-arm, open-label, multicenter, stratified study of soquelitinib versus physician's choice standard of care (SOC) treatment (selected single agents) in participants with relapsed/refractory (R/R) peripheral T-cell lymphoma not ...

DRUG: Soquelitinib

DRUG: Belinostat

DRUG: Pralatrexate

Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma

This is a Phase II clinical trial testing the use of two antigen-directed therapies, inotuzumab and blinatumomab, as part of induction therapy for children and young adults with newly diagnosed B-cell precursor acute lymphoblastic leukemia and lympho...

DRUG: Dexamethasone

DRUG: Vincristine

DRUG: Inotuzumab

DRUG: Blinatumomab

DRUG: Dasatinib

PROCEDURE: IT MHA

DRUG: Cyclophosphamide

DRUG: Cytarabine

DRUG: Methotrexate

DRUG: 6-Mercaptopurine

DRUG: Calaspargase

DRUG: Daunorubicin

DRUG: Thioguanine

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuz...

This is a Phase I/II, multicenter, open-label, dose-escalation study designed to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of a novel T-Cell bispecific (TCB), glofitamab, administered by intravenous (IV) infusion as a sing...

DRUG: Glofitamab

DRUG: Obinutuzumab

DRUG: Tocilizumab

Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma

The goal of this clinical trial is to learn about treatment for people with B-cell lymphoma that did not respond to treatment or that has gotten worse after treatment. The aim of this trial is to answer the following questions: * If it is realistic ...

RADIATION: Bridging radiation therapy

BIOLOGICAL: Liso-cel

RADIATION: Post-infusion radiation

Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymph...

This phase Ib trial tests the safety and effectiveness of tafasitamab, acalabrutinib, and obinutuzumab in treating patients with previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). CLL and SLL are types of ca...

DRUG: Acalabrutinib

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

PROCEDURE: Echocardiography

BIOLOGICAL: Obinutuzumab

OTHER: Questionnaire Administration

BIOLOGICAL: Tafasitamab

CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted...

The major morbidities of allogeneic hematopoietic stem cell transplant with non-human leukocyte antigen (HLA) matched siblings are graft vs host disease (GVHD) and life threatening infections. T depletion of the donor hematopoietic stem cell graft is...

DEVICE: CliniMACS Cell Processing System for TCRαβ + T Cell and CD45RA Depleted Peripheral Stem Cell Addback

Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or R...

This is a phase Ib study to establish safety of Axi-Cel-2 in patients with Large B Cell Lymphoma (LBCL) who are at high risk of relapse.

DRUG: Axicabtagene Ciloleucel

Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies

This phase II trial tests whether loncastuximab tesirine works to shrink tumors in patients with B-cell malignancies that have come back (relapsed) or does not respond to treatment (refractory). Loncastuximab tesirine is a monoclonal antibody, called...

BIOLOGICAL: Loncastuximab Tesirine

A Long-term Extension Study of PCI-32765 (Ibrutinib)

The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been completed ac...

DRUG: Ibrutinib

Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Dif...

This phase II trial evaluates whether loncastuximab tesirine and rituximab followed by dose-adjusted doxorubicin, etoposide, vincristine, cyclophosphamide, and prednisone works to treat patients with high risk diffuse large B-cell lymphoma. Loncastux...

DRUG: Cyclophosphamide

DRUG: Doxorubicin

DRUG: Etoposide

BIOLOGICAL: Loncastuximab Tesirine

DRUG: Prednisone

BIOLOGICAL: Rituximab

DRUG: Vincristine

Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MC...

To learn if the chemotherapy-free combination of pirtobrutinib (also called LOXO-305) and rituximab can help provide long term remission in low and intermediate risk MCL.

DRUG: Rituximab

DRUG: Pirtobrutinib

Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Pat...

This phase II trial investigates how well modified VR-CAP (bortezomib, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, and cytarabine hydrochloride) and acalabrutinib as first line therapy work in treating transplant-eligible pati...

DRUG: Acalabrutinib

DRUG: Bortezomib

DRUG: Cyclophosphamide

DRUG: Cytarabine

DRUG: Doxorubicin Hydrochloride

DRUG: Prednisone

BIOLOGICAL: Rituximab

BIOLOGICAL: Rituximab and Hyaluronidase Human

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infect...

This phase II clinical trial tests how well the cytomegalovirus-modified vaccinica Ankara (CMV-MVA) Triplex vaccine given to human leukocyte antigens (HLA) matched related stem cell donors works to prevent cytomegalovirus (CMV) infection in patients ...

PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation

PROCEDURE: Biospecimen Collection

DRUG: Granulocyte Colony-Stimulating Factor

DRUG: Hematopoietic Cell Transplantation Conditioning Regimen

BIOLOGICAL: Multi-peptide CMV-Modified Vaccinia Ankara Vaccine

PROCEDURE: Pheresis

DRUG: Placebo Administration

DRUG: Stem Cell Mobilization Therapy

A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluro...

The primary purpose of the study is to assess the pharmacokinetics (PK) profile of pembrolizumab following subcutaneous (SC) injection of pembrolizumab coformulated with hyaluronidase, and to evaluate the objective response rate (ORR) of pembrolizuma...

BIOLOGICAL: Pembrolizumab (+) Berahyaluronidase alfa

Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies

The primary purpose of this study is to determine safety, feasibility, and the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) of CD22 Chimeric Antigen Receptor T-Cell Therapy (CART) cells when administered 28 to 42 days after an infusio...

DRUG: CD22CART infusion

DRUG: Tisagenlecleucel

A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cel...

This study is researching a combination of 2 experimental drugs, referred to as "study drugs", called odronextamab (also known as REGN1979) and cemiplimab (also known as REGN2810). The study is focused on patients who have relapse/refractory aggressi...

DRUG: cemiplimab

DRUG: odronextamab

Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells with Chimeric...

The study is designed to examine the feasibility and safety of collecting autologous hematopoietic stem cells (HSCs) to be combined with CAR T-cell therapy for patients with relapsed/refractory (r/r) hematological disease. The study will evaluate fea...

BIOLOGICAL: autologous hematopoietic stem cells added to planned CAR T

Safe Accelerated Venetoclax Escalation in CLL

This research study is trying to determine which patients with newly diagnosed or relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), as grouped by their risk for tumor lysis syndrome (TLS), are able to safely ...

DRUG: Venetoclax

DRUG: Obinutuzumab

DRUG: Rituximab

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in P...

The purpose of this study is to compare the effectiveness and safety of golcadomide in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy vs placebo in combination with R-CHOP chemotherapy in ...

DRUG: Golcadomide

DRUG: Placebo

DRUG: Rituximab

DRUG: Cyclophosphamide

DRUG: Doxorubicin

DRUG: Vincristine

DRUG: Prednisone

A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Di...

The overarching goals of this study are to measure levels of circulating tumor DNA (ctDNA) in patients with early stage diffuse large B cell lymphoma (DLBCL), to assess the change in ctDNA during treatment in order to prospectively identify markers o...

DRUG: Rituximab Prednisone

DRUG: Cyclophosphamide

DRUG: Doxorubicin

DRUG: Vincristine

DRUG: Prednisone

Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ H...

This is a first-in-human phase 1 study of SYNCAR-001 + STK-009 in patients with CD19+ hematologic malignancies.

DRUG: SYNCAR-001

DRUG: STK-009

DRUG: Cyclophosphamide

DRUG: Fludarabine

Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Pos...

This phase Ib/II clinical trial tests the safety, side effects, and effectiveness of mosunetuzumab with chemotherapy for the treatment of patients with untreated, c-Myc rearrangement positive, high grade B cell lymphoma or diffuse large B cell lympho...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration and Biopsy

PROCEDURE: Computed Tomography

DRUG: Cyclophosphamide

DRUG: Doxorubicin

PROCEDURE: Echocardiography

DRUG: Etoposide

PROCEDURE: Magnetic Resonance Imaging

BIOLOGICAL: Mosunetuzumab

PROCEDURE: Multigated Acquisition Scan

PROCEDURE: Positron Emission Tomography

DRUG: Prednisone

DRUG: Vincristine

A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adu...

To find the highest tolerable dose of JV-213 (a type of autologous CAR T cell therapy) that can be given to patients who have B-cell lymphoma that is relapsed or refractory.

DRUG: JV-213

PROCEDURE: Leukapheresis

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R...

Follicular lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This study will as...

DRUG: Epcoritamab

DRUG: Prednisone

DRUG: Rituximab

DRUG: Lenalidomide

DRUG: Doxorubicin

DRUG: Vincristine

DRUG: Cyclophosphamide

DRUG: Obinutuzumab

DRUG: Bendamustine

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in treating patients with peripheral T-cell lymphoma. Duvelisib may stop the grow...

DRUG: Cyclophosphamide

DRUG: Doxorubicin

DRUG: Vincristine

DRUG: Prednisone

DRUG: Etoposide

DRUG: Duvelisib

DRUG: Oral azacitidine

Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma

This phase II trial studies how well polatuzumab vedotin and combination chemotherapy work in treating patients with previously untreated double, triple hit lymphoma, Double Expressor Lymphoma or High-Grade B Cell Lymphoma. Polatuzumab vedotin is a m...

DRUG: Prednisone

DRUG: Prednisolone

DRUG: Methylprednisolone

BIOLOGICAL: Rituximab

DRUG: Polatuzumab Vedotin

DRUG: Cyclophosphamide

DRUG: Doxorubicin Hydrochloride

Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia

This study will evaluate fixed-duration therapy with pirtobrutinib and obinutuzumab given over 12 cycles (approximately 1 year) as first-line treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL or SLL).

DRUG: Pirtobrutinib

DRUG: Obinutuzumab

A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)

A Phase 1/2 Study of bbT369, a dual targeting CAR T cell drug product with a gene edit, in Relapsed and/or Refractory B cell Non-Hodgkin's Lymphoma.

BIOLOGICAL: bbT369

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymp...

This study will assess safety and feasibility of infusing genetically modified autologous T cells transduced to express a chimeric antigen receptor targeting the B cell surface antigen Cluster of Differentiation 19 (CD19)

DRUG: Fludarabine

DRUG: Cyclophosphamide

BIOLOGICAL: anti-CD19 CAR-T cells

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients with Recurrent or Refractory B-Ce...

This phase I trial studies the side effects and best dose of CD19/CD20 chimeric antigen receptor (CAR) T-cells when given together with chemotherapy, and to see how effective they are in treating patients with non-Hodgkin's B-cell lymphoma or chronic...

BIOLOGICAL: Chimeric Antigen Receptor T-Cell Therapy

DRUG: Cyclophosphamide

DRUG: Fludarabine Phosphate

BIOLOGICAL: Tocilizumab

Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma

The purpose of this study is to test a new medication called Mosunetuzumab to see if it can help people with Extranodal Marginal Zone Lymphoma (EMZL). This study will include people who have not yet received any treatment for cancer and whose cancer ...

DRUG: Mosunetuzumab

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxo...

The purpose of this study is to compare the efficacy and safety of glofitamab in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) vs Pola-R-CHP in participants with previously untreated C...

DRUG: Glofitamab

DRUG: Polatuzumab vedotin

DRUG: Rituximab

DRUG: Cyclophosphamide

DRUG: Doxorubicin

DRUG: Prednisone

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing

This is a single arm pilot study for patients with hematologic malignancies receiving unrelated or haploidentical related mobilized peripheral stem cells (PSCs) using the CliniMACS system for alpha/beta T cell depletion plus CD19+ B cell depletion wi...

DEVICE: Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi)

LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma

The purpose of this study is to test the effects of a drug called Voraxaze when it's routinely given in combination with methotrexate and rituximab, the standard treatment for CNSL.

DRUG: Methotrexate

DRUG: Rituximab

DRUG: leucovorin

DRUG: Glucarpidase

Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refr...

This is a two-arm, open-label, phase Ib single-site study with expansion cohorts testing the addition of mosunetuzumab to intensive platinum-based salvage chemotherapy in patients with relapsed/refractory aggressive B cell lymphoma. The hypothesis of...

DRUG: Mosunetuzumab

DRUG: DHAX

DRUG: ICE

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MP...

This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 sub...

DRUG: LP-118

Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma

Therapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against refractory lymphoma, however not all tumors respond or remain in response to CD19 targeted CAR-T cells. We posit that CAR-T cells expressing BAFF (BAFF CAR-T cel...

DRUG: BAFF CAR-T

Ultra Low Dose Radiation Delivered Before or After Chemotherapy-Free Targeted Therapy in Treating Pa...

This phase II trial studies how well ultra low dose radiation works before or after chemotherapy-free targeted therapy in treating patients with mantle cell lymphoma that has come back or does not respond to treatment. Radiation therapy uses high ene...

DRUG: Low Dose Radiation Therapy

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Pl...

The purpose of this study is to assess the safety, tolerability, drug levels, and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymp...

DRUG: Relatlimab

DRUG: Nivolumab

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignanc...

This study is a Phase 1 dose-escalation and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV111. The study will enroll patients with relapsed/refractory large B-cell lymphoma (LBCL) and chronic lymphocytic leukemia (CLL)...

GENETIC: UB-VV111

DRUG: rapamycin

Epcoritamab-CAR T Cells for Large B-cell Lymphomas

This study investigates the feasibility and efficacy of epcoritamab treatment before CAR T cells. This study also investigates if, when patients have residual lymphoma after CAR T cells, epcoritamab can help to effectively treat that lymphoma.

DRUG: Epcoritamab

Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NP...

A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/ MLL1r, NPM1 mutations), DLBCL, MM, and CLL/SLL.

DRUG: BMF-219

Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leu...

This phase I/II trial studies the side effects and best dose of inotuzumab ozogamicin and to see how well it works when given together with combination chemotherapy in treating patients with acute lymphoblastic leukemia. Inotuzumab ozogamicin is a mo...

BIOLOGICAL: Blinatumomab

DRUG: Cyclophosphamide

DRUG: Cytarabine

DRUG: Dexamethasone

BIOLOGICAL: Inotuzumab Ozogamicin

OTHER: Laboratory Biomarker Analysis

DRUG: Mercaptopurine

DRUG: Methotrexate

DRUG: Prednisone

BIOLOGICAL: Rituximab

DRUG: Vincristine

Testing Continuous Versus Intermittent Treatment with the Study Drug Zanubrutinib for Older Patients...

This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (previously ...

DRUG: Zanubrutinib

BIOLOGICAL: Rituximab

OTHER: Patient Observation

PROCEDURE: Bone Marrow Biopsy

OTHER: Fludeoxyglucose F-18

PROCEDURE: Positron Emission Tomography

PROCEDURE: Computed Tomography

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Esophagogastroduodenoscopy

PROCEDURE: Colonoscopy

PROCEDURE: Biospecimen Collection

OTHER: Questionnaire Administration

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Follow...

This phase I trial studies the safety and side effects of cytomegalovirus (CMV) specific CD19-chimeric antigen receptor (CAR) T-cells along with the CMV-modified vaccinia Ankara (MVA) triplex vaccine following a stem cell transplant in treating patie...

BIOLOGICAL: Anti-CD19-CAR CMV-specific T-lymphocytes

PROCEDURE: Autologous Hematopoietic Stem Cell Transplantation

BIOLOGICAL: Multi-peptide CMV-Modified Vaccinia Ankara Vaccine

PROCEDURE: Myeloablative Conditioning

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin ...

This phase I trial studies the side effect and best dose of ibrutinib in combination with rituximab, etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride in treating patients with human immunodeficiency virus (H...

DRUG: Cyclophosphamide

DRUG: Doxorubicin Hydrochloride

DRUG: Etoposide

BIOLOGICAL: Filgrastim

DRUG: Ibrutinib

OTHER: Laboratory Biomarker Analysis

BIOLOGICAL: Pegfilgrastim

OTHER: Pharmacological Study

DRUG: Prednisone

BIOLOGICAL: Rituximab

DRUG: Vincristine Sulfate

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patient...

The purpose of this Phase 2/3 study is to evaluate efficacy and safety of the combination of selinexor and R-GDP (SR-GDP) in patients with RR DLBCL who are not intended to receive hematopoetic stem cell transplantation (HSCT) or chimeric antigen rece...

DRUG: Selinexor (combination therapy)

DRUG: Placebo matching for Selinexor (combination therapy)

DRUG: Rituximab (combination therapy)

DRUG: Gemcitabine (combination therapy)

DRUG: Dexamethasone (combination therapy)

DRUG: Cisplatin (combination therapy)

DRUG: Selinexor (continuous therapy)

DRUG: Placebo matching for Selinexor (continuous therapy)

Zanubrutinib and Venetoclax in CLL (ZANU-VEN)

This study is being done to test the effectiveness of zanubrutinib in combination with venetoclax in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

DRUG: Venetoclax

DRUG: Zanubrutinib

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

This study evaluates a fenretinide phospholipid suspension for the treatment of T-cell non-Hodgkin's lymphoma (NHL).

DRUG: Fenretinide

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

The purpose of this study is to determine the safety of administering obinutuzumab as a single agent alone and in combination with ifosfamide, carboplatin, and etoposide (ICE) chemotherapy and determine the response rate of this treatment for childre...

DRUG: Obinutuzumab

DRUG: Liposomal ARA-C

DRUG: Ifosfamide

DRUG: Carboplatin

DRUG: Etoposide

Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethaso...

BACKGROUND: * Primary CNS lymphoma (PCNSL) is a rare subtype of diffuse large B-cell lymphoma. * The outcome for patients with this diagnosis is significantly worse than for that of systemic DLBCL. Most treatment approaches in the past have included...

DRUG: Isavuconazole

DRUG: TEDDI

BIOLOGICAL: Rituximab

DRUG: Cytarabine

DRUG: TEDD

DRUG: Ibrutinib (Arms 2, 3 and 4)

DRUG: Methotrexate

DRUG: Ibrutinib (Arm 1 - Closed with Amendment G)

DRUG: Ibrutinib (Arm 4)

Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults ...

The most common types of mature B-cell lymphomas (MBLs) in children are Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). Initial treatment cures 90% - 95% of children with these malignancies, leaving a very small population of relapse...

DRUG: Epcoritamab

Pembro Plus CAR T-cell Therapy in R/R in PMBCL

This research study is evaluating the combination of drugs, pembrolizumab with chimeric antigen receptor (CAR) T-cell therapy, as a possible treatment for primary mediastinal B-cell lymphoma that has recurred after prior treatment. The names of the ...

DRUG: Pembrolizumab

DRUG: Lymphodepletion Chemotherapy

DRUG: Chimeric Antigen Receptor (CAR) Therapy Infusion

PROCEDURE: Leukapheresis

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against...

This study is researching an experimental drug called odronextamab, referred to as study drug, when used in combination with chemotherapy. The study is focused on patients with diffuse large B-cell lymphoma (DLBCL) that have not been treated before (...

DRUG: Odronextamab

DRUG: Rituximab

DRUG: Cyclophosphamide

DRUG: Doxorubicin

DRUG: Vincristine

DRUG: Prednisone/Prednisolone

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further radiation). followed by...

BIOLOGICAL: HSCT with TBI Regimen

BIOLOGICAL: HSCT with Non-TBI Regimen

Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relaps...

This is an open label, non-randomized, phase 1 study of anti-CD19 CAR-T cells against relapsed CD19 positive NHL, CLL and ALL based in a lymphodepletion regimen (fludarabine and cyclophosphamide) and using a CellReGen-based process for manufacturing ...

BIOLOGICAL: Anti-CD19 CAR-T cells

Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)

SC262-101 is a Phase 1 study to evaluate SC262 safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.

DRUG: SC262

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.

DRUG: NX-5948

A Study of NX-1607 in Adults With Advanced Malignancies

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.

DRUG: NX-1607

DRUG: Paclitaxel

A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic...

The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing of ibrutinib is either proactively reduced or reactively modified in response to adverse events (AEs).

DRUG: Ibrutinib

DRUG: Venetoclax

A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant

The purpose of this study is to find out whether it is practical to use a newer way to calculate melphalan dose given (called population PK model) in BEAM chemotherapy before AHCT. Standard dose is fixed for everybody and is calculated using height a...

OTHER: Pharmacokinetics

Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refra...

This phase I trial tests the safety, side effects, and best dose of genetically engineered cells called EGFRt/19-28z/IL-12 CAR T cells, and to see how they work in treating patients with hematologic malignancies that makes a protein called CD19 (CD19...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

DRUG: Cyclophosphamide

PROCEDURE: Echocardiography

BIOLOGICAL: EGFRt/19-28z/IL-12 CAR T-lymphocytes

DRUG: Fludarabine Phosphate

PROCEDURE: Leukapheresis

PROCEDURE: Multigated Acquisition Scan

PROCEDURE: Positron Emission Tomography

Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell ...

This phase II trial studies the side effects of acalabrutinib, obinutuzumab, and glofitamab and how well they work together for treating patients with mantle cell lymphoma that has come back after a period of improvement (relapsed) or that has not re...

DRUG: Acalabrutinib

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

PROCEDURE: Echocardiography

BIOLOGICAL: Glofitamab

PROCEDURE: Multigated Acquisition Scan

BIOLOGICAL: Obinutuzumab

PROCEDURE: Positron Emission Tomography

Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)

Participants are invited to take part in this research study because they have relapsed (cancer has come back) or refractory (cancer has not responded to treatment) B-cell Lymphoma and will be undergoing CAR T-cell Therapy. This research is being do...

RADIATION: Adaptive Bridging Radiation Therapy (ABRT)

Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

This phase I trial evaluates the side effects and usefulness of axicabtagene clioleucel (a CAR-T therapy) and find out what effect, if any, it has on treating patients with HIV-associated aggressive B-cell non-Hodgkin lymphoma that has come back (rel...

BIOLOGICAL: Axicabtagene Ciloleucel

DRUG: Cyclophosphamide

DRUG: Fludarabine

A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intrav...

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). The purpose of this study is to assess the change in disease activity of epcoritamab when combined with intravenous a...

DRUG: Epcoritamab

DRUG: Cyclophosphamide

DRUG: Rituximab

DRUG: Vincristine

DRUG: Doxorubicin

DRUG: Prednisone

Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma

The goal of this clinical trial is to learn about how a combination of tazemetostat and venetoclax in people with relapsed/refractory Non-Hodgkin Lymphoma (R/R NHL). The main questions that this trial aims to answer are what is the best dose of venet...

DRUG: Venetoclax

DRUG: Tazemetostat

Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for New...

This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with the ...

PROCEDURE: Biospecimen Collection

BIOLOGICAL: Blinatumomab

PROCEDURE: Bone Marrow Aspiration and Biopsy

DRUG: Cyclophosphamide

DRUG: Cytarabine

DRUG: Dasatinib

DRUG: Dexamethasone

DRUG: Doxorubicin Hydrochloride

PROCEDURE: Echocardiography

PROCEDURE: Electrocardiography

PROCEDURE: Lumbar Puncture

DRUG: Mesna

DRUG: Methotrexate

PROCEDURE: Multigated Acquisition Scan

DRUG: Ponatinib Hydrochloride

DRUG: Prednisone

DRUG: Vincristine Sulfate

SynKIR-310 for Relapsed/Refractory B-NHL

This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refractory B-NHL.

BIOLOGICAL: SynKIR-310

A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL a...

This is a Phase II single-center open label trial of the combination of ATRA and pembrolizumab treatment in patients with histologically proven, relapsed or refractory Hodgkin Lymphoma or B-Non-Hodgkin-lymphoma.

DRUG: ATRA

DRUG: Pembrolizumab

Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma

First-in-human, open-label, dose-finding and dose-expansion study of UCART20x22 administered intravenously in subjects with relapsed or refractory B-Cell Non-Hodgkin Lymphoma (B-NHL). The purpose of this study is to evaluate the safety and clinical a...

BIOLOGICAL: UCART20x22

BIOLOGICAL: CLLS52

A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants W...

Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries. The purpose of this study is to assess how well ABBV-453 works adult participants with relapsed/refractory (R/R) untreated CLL/small lymphocytic lymphoma (SLL). Adve...

DRUG: Obinutuzumab

DRUG: ABBV-453

A Phase 2 Study of Firi-cel in Patients with Relapsed/refractory Large B-cell Lymphoma

This is a prospective, open-label, multi-center clinical study designed to evaluate the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of firicabtagene autoleucel (firi-cel), a CD22-directed autologous Chimeric...

DRUG: Fludarabine (Conditional therapy)

DRUG: Cyclophosphamide Monohydrate (Conditional therapy)

DRUG: firi-cel (Experimental drug)

Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma

In this research study is looking to see how safe and effective belantamab mafodotin is in relapsed or refractory plasmablastic lymphoma or ALK+ large B-cell lymphoma. * This research study involves the study drug belantamab mafodotin. * Belantamab ...

DRUG: Belantamab Mafodotin

AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B...

Children, adolescents, and young adults with malignant and non-malignant conditionsundergoing an allogeneic stem cell transplantation (AlloSCT) will have the stem cells selected utilizing α/β CD3+/CD19+ cell depletion. All other treatment is standard...

DRUG: alpha beta depletion

A Vaccine (VSV-hIFNβ-NIS) with or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab...

This phase I trial studies the best dose and side effects of the VSV-hIFNβ-NIS vaccine with or without cyclophosphamide and combinations of ipilimumab, nivolumab, and cemiplimab in treating patients with multiple myeloma, acute myeloid leukemia or ly...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

DRUG: Cyclophosphamide

PROCEDURE: Positron Emission Tomography

BIOLOGICAL: Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter

PROCEDURE: Single Photon Emission Computed Tomography

BIOLOGICAL: Cemiplimab

DRUG: Ruxolitinib

A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas

ATG-031 study (alias: PERFORM) is a multicenter, open-label, Phase 1 study of ATG-031 in patients with advanced solid tumors or B-NHL. The study design includes a Dose Escalation Phase and a Dose Expansion Phase, and will enroll patients with advance...

DRUG: ATG-031

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

This is a randomized, open-label study in adult patients who have completed standard first line of therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual d...

GENETIC: cemacabtagene ansegedleucel

BIOLOGICAL: ALLO-647

DRUG: Fludarabine

DRUG: Cyclophosphamide

DEVICE: Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™

Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and ...

Subjects on this study have a type of lymph gland cancer called Non-Hodgkin Lymphoma, acute lymphocytic leukemia, or chronic Lymphocytic Leukemia (these diseases will be referred to as "lymphoma" or "leukemia"). The lymphoma or leukemia has come back...

GENETIC: Dose Escalation Phase:CD19.CAR/28 and CD19.CAR/28137 T cells

GENETIC: Expansion Phase: CD19.CAR/28 and CD19.CAR/28137 T cells

Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs f...

This study will combine both T cells and antibodies in order to create a more effective treatment. The treatment tested in this study uses modified T-cells called Autologous T Lymphocyte Chimeric Antigen Receptor (ATLCAR) cells targeted against the k...

DRUG: CAR.k.28

DRUG: Fludarabine

DRUG: Cyclophosphamide

DRUG: Bendamustine

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R...

Follicular Lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This study will as...

DRUG: Epcoritamab

DRUG: Rituximab

DRUG: Lenalidomide

A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymp...

This is a First-in-Human Phase I trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas.

DRUG: ATG-101

A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Ag...

The study is researching an experimental drug called REGN5837 in combination with another experimental drug, odronextamab (called "study drugs"). The aim of the study is to see how safe and tolerable the study drugs are, and to define the recommende...

DRUG: Odronextamab

DRUG: REGN5837

Safety of Myeloablative Conditioning, Orca-T, and Allogeneic, Donor-Derived CD19/CD22-CAR (Chimeric ...

To assess the safety of administering allogenic, donor-derived CD19/CD22-CAR T cells that meet established release specifications in adults with B-cell ALL following a myeloablative conditioning regimen and Orca-T to determine if this will augment gr...

DRUG: Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector (CD19/CD22-BBz) chimeric antigen receptor (CAR)

DRUG: Treg CD34+HSPC (Orca-T)

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab i...

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purpose of this study is to assess the safety and tolerability of epcoritamab in combination with anti-neoplastic ...

DRUG: Epcoritamab

DRUG: Lenalidomide

DRUG: Ibrutinib

DRUG: Rituximab

DRUG: Cyclophosphamide

DRUG: Doxorubicin Hydrochloride [HCl]

DRUG: Prednisone

DRUG: Polatuzumab Vedotin

DRUG: Venetoclax

DRUG: CC-99282

DRUG: Pirtobrutinib

Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

This study aimed to evaluate the efficacy of a novel regimen consisting of polatuzumab vedotin in combination with rituximab, gemcitabine, dexamethasone, and cisplatin (PV-RGDP) for the treatment of diffuse large B-cell lymphoma that either came back...

DRUG: Polatuzumab vedotin (PV)

DRUG: Rituximab

DRUG: Hyaluronidase

DRUG: Gemcitabine

DRUG: Cisplatin

DRUG: Dexamethasone

DRUG: GCSF

CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

This is a Phase I/II, interventional, single-arm, open-label, treatment study designed to evaluate the safety and efficacy of Interleukin-7 and Interleukin-15 (IL-7/IL-15) manufactured chimeric antigen receptor (CAR)-20/19-T cells as well as the feas...

BIOLOGICAL: 8/12-Day Production of Car-T Cells

BIOLOGICAL: 8/12-Day Production of Cryopreserved Car-T Cells

BIOLOGICAL: 12-Day Production of Car-T Cells

P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

Phase 1 study comprised of open-label, dose escalation and expansion cohort study of P-CD19CD20-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed/refractory B cell malignancies

BIOLOGICAL: P-CD19CD20-ALLO1

DRUG: Rimiducid

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relap...

The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R\^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as deter...

DRUG: Zanubrutinib

DRUG: Rituximab

DRUG: Lenalidomide

DRUG: Obinutuzumab

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide fo...

This phase I trial studies the side effects and best dose of mosunetuzumab when given together with polatuzumab vedotin and lenalidomide in treating patients with diffuse large B-cell lymphoma (DLBCL) that has come back after a period of improvement ...

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

DRUG: Lenalidomide

BIOLOGICAL: Mosunetuzumab

DRUG: Polatuzumab Vedotin

PROCEDURE: Positron Emission Tomography

Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKAL...

Patients have a type of cancer called NHL, Multiple Myeloma (MM) or CLL that has come back or has not gone away after treatment. There is no standard treatment for the cancer at this time or the currently used treatments do not work completely in all...

BIOLOGICAL: Kappa CD28 T cells

A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

CP-MGD024-01 is a Phase 1, open-label, multi-center study of MGD024 as a single agent in participants with select blood cancers that have not responded to treatment with standard therapies or who have relapsed after treatment. The study is designed t...

DRUG: MGD024

CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First...

This phase I trial tests the safety, side effects, and best dose of autologous anti-CD19 CAR-expressing T lymphocytes (CD19-CAR T cells) in older adults with B-cell acute lymphoblastic leukemia. Chimeric antigen receptor (CAR) T-cell therapy is a typ...

DRUG: Autologous Anti-CD19 CAR-expressing T Lymphocytes

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration and Biopsy

DRUG: Cyclophosphamide

DRUG: Fludarabine

PROCEDURE: Leukapheresis

OTHER: Questionnaire Administration

Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follic...

This phase II trial studies how well obinutuzumab, ibrutinib, and venetoclax work in treating patients with previously untreated stage II-IV follicular lymphoma. Immunotherapy with obinutuzumab may induce changes in body's immune system and may inter...

DRUG: Ibrutinib

BIOLOGICAL: Obinutuzumab

DRUG: Venetoclax

Charity Navigator

HealthTree Foundation is a qualified 501(c)(3) tax-exempt organization.

Tax ID 45-5354811

Education

Community

Cure Hub

Get Involved

About us

Need Help?

Legal Info

Get the Latest B-Cell Lymphoma Updates, Delivered to You.

Education

Community

Cure Hub

Get Involved

About us

Need Help?

Legal Info